Interventional dosing system and method
The closed-loop drug delivery system addresses the challenge of unpredictable adverse drug reactions by monitoring patient conditions and adjusting drug administration, facilitating timely intervention and reducing the need for hospital visits.
Patent Information
- Application Number
- JP2024114515
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-09-24
- Filing Date
- 2024-07-18
- Publication Date
- 2024-12-03
AI Technical Summary
Existing drug administration systems fail to predict and respond effectively to adverse side effects in patients, leading to burdensome monitoring and potential life-threatening conditions like Cytokine Release Syndrome (CRS), necessitating frequent hospital visits and invasive treatments.
A closed-loop drug delivery system with integrated sensors and controllers that monitor patient conditions and adjust or interrupt drug administration in response to detected biological markers, allowing for timely intervention with counteractive drugs.
Enables early detection and management of adverse side effects, reducing the burden on healthcare providers and patients by allowing self-administration of interventions at home or managed care sites, thereby enhancing safety and reducing the need for frequent hospital visits.
Smart Images

Figure 2024167180000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 735,476, filed Sep. 24, 2018, the entire contents of which are incorporated herein by reference.
[0002] FIELD OF THE DISCLOSURE The present disclosure relates generally to drug delivery systems and methods, and more particularly to interventional drug dosing techniques that respond to changes in a monitored patient condition. [Background technology]
[0003] Drugs are administered to treat a variety of conditions and diseases. The use of certain drugs may result in unintended side effects, including those that are harmful to the patient's health. It is not always possible to predict whether a patient will have an adverse reaction to an administered drug. As a result, depending on the severity of the potential side effects, it may be necessary to monitor the patient's condition during and / or after drug administration. If a patient unexpectedly develops adverse side effects, administration of the drug may be interrupted or the dose may be adjusted and / or another drug may be administered to counteract the side effects. The effectiveness of such interventional drug treatments depends on early detection of side effects and timely administration of a counteractive drug.
[0004] As described in further detail below, the present disclosure describes systems and methods for patient monitoring and interventional dosing techniques that embody advantageous alternatives to existing systems and methods that may address one or more of the problems or needs referenced herein, as well as provide other benefits and advantages. Summary of the Invention [Means for solving the problem]
[0005] An aspect of the disclosure provides a system including one or more reservoirs, each filled or fillable with one or more drug products, a dosing member, a fluid delivery system, one or more sensors, and, optionally, a controller. The one or more reservoirs may include a first reservoir filled or fillable with a first drug product. The dosing member may be insertable into a patient and may be connected or connectable in fluid communication with the first reservoir. The fluid delivery system may be operable to deliver the first drug product from the first reservoir to the patient via the dosing member. The one or more sensors may be operable to sense one or more biological conditions of the patient. The controller may be configured to control operation of the fluid delivery system based on an output from the one or more sensors. In some embodiments, the controller may be configured to operate the fluid delivery system to interrupt, terminate, or inhibit delivery of the first drug product to the patient based on a first biological condition sensed by the one or more sensors and / or a second biological condition sensed by the one or more sensors. Further, in some embodiments, the one or more reservoirs may include a second reservoir filled or fillable with a second drug product held separately from the first drug product, and the controller may be configured to operate the fluid delivery system to initiate delivery of the second drug product to the patient based on the first biological condition sensed by the one or more sensors and / or the second biological condition sensed by the one or more sensors. Further, in some embodiments, the second drug product may include a therapeutic agent for treating a condition or syndrome induced by administration of the first drug product.
[0006] Another aspect of the disclosure provides a method including: (a) operating a fluid delivery system to deliver a first drug product from a reservoir to a patient via a dosing member; (b) sensing, by one or more sensors, one or more biological conditions of the patient during, before, and / or after the first drug product is delivered; and, optionally, (c) automatically or manually operating the fluid delivery system by a controller to interrupt, terminate, or inhibit delivery of the first drug product to the patient based on the one or more sensed biological conditions. The method may further include (d) automatically or manually operating the fluid delivery system by a controller to initiate delivery of a second drug product from a second reservoir to the patient based on the one or more sensed biological conditions. In some embodiments, the second drug product may include a therapeutic agent for treating or managing a condition or syndrome induced by administration of the first drug product.
[0007] The present disclosure will be more fully understood from the following description taken in conjunction with the accompanying drawings, in which: Some of the drawings may be simplified by omitting selected elements to more clearly show other elements. The omission of such elements in some of the drawings does not necessarily indicate the presence or absence of the particular element in any of the illustrative embodiments, unless expressly described in the corresponding written specification. Additionally, none of the drawings are necessarily drawn to scale. [Brief description of the drawings]
[0008] [Figure 1] FIG. 1 is a schematic diagram of a drug delivery system according to an embodiment of the present disclosure. [Diagram 2] FIG. 2 is a block diagram of a method of operating a drug delivery system, such as the drug delivery system shown in FIG. 1, according to one embodiment of the present disclosure. [Diagram 3] FIG. 1 is a cross-sectional view of an embodiment of a drug delivery system including an on-body injector. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] The present disclosure relates generally to a closed-loop drug delivery and biosensing system and method for monitoring the condition of a patient undergoing drug therapy and for providing interventional medication if the patient develops adverse side effects to the drug therapy. The systems and methods disclosed herein are particularly suited to patients at risk of developing Cytokines Release Syndrome (CRS) as a result of drug therapy, although they may also be used outside of this particular application.
[0010] CRS is a form of systemic inflammatory response that occurs as a side effect after patients receive immunotherapy agents. CRS can occur, for example, after T cell induction therapy, including bispecific T cell induction (e.g., BiTE®) antibody constructs and chimeric antigen receptor (CAR) T cell receptors, such as blinatumomab (e.g., BLINCYTO®). CRS can be life-threatening and, in certain cases, fatal. Thus, hospitalization is recommended after immunotherapy treatment so that medical personnel can closely monitor patients for symptoms of CRS. Even if patients are not hospitalized, patients may be instructed to remain near the place where they received immunotherapy treatment, sometimes for a period of four weeks or more, so that emergency medical care can be provided if there are signs of CRS. Additionally, patients may be required to be monitored at least once a day for signs of CRS for one week after immunotherapy treatment at a certified medical institution. Such monitoring can be burdensome for both patients and medical providers.
[0011] Antipyretics and / or intravenous fluids may be administered to help manage CRS. Additionally or alternatively, anti-cytokine agents such as corticosteroids (e.g., dexamethasone) and / or anti-interleukin-6 (IL-6) receptor antibodies (e.g., tocilizumab) may be administered. The efficacy of such anti-cytokine treatments may depend on administration at an early stage of CRS. Therefore, it may be important to identify the first warning signs of CRS and take prompt medical action.
[0012] Anti-cytokine agents and other drug products for treating CRS are usually in the form of injectable fluids. Patients who are uncomfortable self-injecting or do not have the necessary training to do so may have to return to a hospital or other medical institution to receive the injection. Given that the patient may be in a weakened state due to cancer or other disease, requiring the patient to return to a hospital or other medical institution may be a significant burden.
[0013] The present disclosure describes systems and methods having various automated or semi-automated features or steps to assist in identifying the onset of CRS or another syndrome or condition induced by current or previous administration of a drug product, and facilitating various interventional medication procedures, including, but not limited to, self-administration of a drug product to treat the induced syndrome or condition. The systems and methods of the present disclosure advantageously facilitate early detection of adverse side effects, such as adverse CRS, and provide timely and appropriate medical intervention. Thus, the burden on healthcare providers to perform regular blood tests and / or other patient monitoring to detect adverse side effects is reduced. Furthermore, patients can monitor and / or mitigate adverse side effects without the need to travel to a centralized management center, such as a hospital. Instead, such tasks can be performed at the self-administration location, including, for example, a managed care site, a wellness clinic, or the patient's home.
[0014] 1 illustrates a drug delivery system 100 according to one embodiment of the present disclosure. The drug delivery system 100 may be associated with a patient 102 who may use the drug delivery system 100 to inject or infuse one or more drug products as part of a treatment regimen. The drug delivery system 100 may communicate information with an external computing device 104 (e.g., a smartphone, a smartwatch, a desktop computer, a server, etc.) via one or more intermediate computing devices and / or one or more networks. Additionally, the external computing device 104 may communicate with the patient 102 and / or one or more other computing devices and patient stakeholders (e.g., a healthcare provider such as a physician or caregiver) directly or indirectly via one or more intermediate computing devices and / or one or more networks.
[0015] In some embodiments, drug delivery system 100 may be defined by multiple discrete components that are assembled together during use. In one such embodiment, drug delivery system 100 may include a bedside infusion pump or other stationary or non-ambulatory infusion pump that is connected during use to one or more drug reservoirs, which are further connected during use to a patient via one or more tubing sets and one or more needles. In alternative embodiments, some or all of the components of drug delivery system 100 may be pre-assembled and / or contained within a single housing or unit. In such alternative embodiments, drug delivery system 100 may be formed as (i) a wearable injector, such as the on-body injector that can be attached to the skin described below in connection with FIG. 3, or a garment-attachable portable infusion pump designed to deliver a drug product via flexible tubing and an infusion set external to the pump housing, or (ii) a handheld injector, such as an autoinjector. In yet another alternative embodiment, the drug delivery system 100 may be formed by any combination of a stationary infusion pump (e.g., a bedside infusion pump), a wearable injector, an autoinjector, and / or a conventional manually operated syringe.
[0016] In some embodiments, the drug delivery system 100 may be portable so that it can be carried or worn by the patient before, after, and / or during drug delivery, while in other embodiments, the drug delivery system 100 may remain in place for the duration of drug delivery.
[0017] The drug delivery system 100 may utilize one or more routes of administration depending on the amount, duration, and / or type of drug to be administered, among other considerations. Such routes of administration may include, but are not limited to, intravenous, intra-arterial, subcutaneous, transdermal, intradermal, intramuscular, intrathecal, intracerebral, epidural, intraocular, nasal, inhalation, oral, and / or topical. In embodiments in which the fluid system 100 is configured to deliver or assist in the delivery of more than one drug product to a patient, different routes of administration may be used for some or all of the drug products, including any combination of the routes of administration mentioned herein or other routes of administration.
[0018] The drug delivery system 100 may include one or more reservoirs, each filled (e.g., pre-filled) or fillable (e.g., filled upon use of the drug delivery system 100) with one or more drug products, sometimes referred to herein as medicaments or drugs. In embodiments in which multiple reservoirs are included, each reservoir may hold each drug product separately such that the drug products cannot be mixed prior to use. The drug products may be, but are not limited to, various biological agents, such as peptides, peptibodies, or antibodies. The drug products may be in fluid or liquid form, although the disclosure is not limited to any particular state. According to some embodiments, the reservoirs may each be defined by a rigid walled cylinder having an internal bore, such as a syringe, vial, or cartridge. In other embodiments, the reservoirs may each be defined by a non-rigid, collapsible pouch, such as an IV bag.
[0019] In some embodiments, the drug delivery system 100 may have a built-in reconstitution subsystem on board for diluting the lyophilized drug into a liquid form. In certain such embodiments, a diluent reservoir may be included for holding a diluent solution, and a lyophilized reservoir may be included for holding the lyophilized compound separately from the diluent solution. Additionally, a fluid drive may be included for mixing the diluent solution in the diluent reservoir with the lyophilized compound in the lyophilized reservoir. In some embodiments, the fluid drive may move the diluent solution from the diluent reservoir to the lyophilized reservoir and / or provide any circulation and / or agitation necessary to obtain complete reconstitution. In some embodiments, a reservoir for an additional final reconstituted drug may be included or may serve as a delivery reservoir from which the reconstituted drug is released to the patient, while in other embodiments, the lyophilized reservoir may serve as a delivery reservoir. In certain embodiments, the reconstitution subsystem may be physically built into the drug delivery system 100, while in other embodiments, the reconstitution subsystem may constitute a separate unit in fluid communication with the drug delivery system 100. Having a separate unit can simplify the reconstitution process for healthcare providers in certain cases.
[0020] In the embodiment shown in FIG. 1, the drug delivery system 100 includes a first reservoir 106 that is filled or fillable with a first drug product, and a second reservoir 108 that is filled or fillable with a second drug product. In some embodiments, the first reservoir 106 and the second reservoir 108 are mechanically interconnected (e.g., as part of a single reservoir assembly) and may in some cases not be able to move relative to one another during drug delivery. Meanwhile, in other embodiments, the first reservoir 106 and the second reservoir 108 are separate from one another and therefore may be free to move independently of one another. In embodiments in which the first drug product is a lyophilized drug, a third reservoir may be included to hold a diluent solution, as described above.
[0021] In some embodiments, the second drug product in the second reservoir 108 may be a therapeutic agent for treating or managing a condition or syndrome induced by administration of the first drug product from the first reservoir 106. In certain such embodiments, the first drug product in the first reservoir 106 may comprise an immunotherapeutic agent, including but not limited to a bispecific T cell-guiding (e.g., BiTE®) antibody construct (e.g., blinatumomab) and / or a chimeric antigen receptor (CAR) T cell receptor (e.g., anti-CD19 CAR-T cell), and the second drug product in the second reservoir 108 may comprise a therapeutic agent for treating or managing any potential CRS induced by administration of the immunotherapeutic agent, including but not limited to antipyretics, anti-cytokine agents (e.g., dexamethasone, methylprednisolone, or other corticosteroids), anti-interleukin-6 (IL-6) receptor antibodies (e.g., tocilizumab), and / or anti-IL-6 chimeric monoclonal antibodies (e.g., siltuximab).
[0022] The drug delivery system 100 may include one or more administration members for establishing fluid or another type of communication between one or more reservoirs and the patient 102. In some embodiments, each administration member may have a first end connected or connectable in fluid communication with a respective reservoir and a second end that is inserted into the patient 102. In some embodiments, the second end may be sharp enough to at least penetrate the patient's skin and enter subcutaneous tissue, veins, arteries, or other anatomical structures. In some embodiments, each administration member may include a cannula. The cannula may include, by way of example and without limitation, a rigid or semi-rigid needle or blunt cannula, or may be in a flexible form. The cannula may be integrated with other elements of the drug delivery system 100, or the cannula may be separate from other elements of the drug delivery system 100 until immediately prior to use. According to certain embodiments, the drug delivery system 100 may further include an inserter or introducer member for introducing the second end of the cannula into the patient, although this is not necessary according to the embodiments of the present disclosure. In certain embodiments, the introducer member may be removed and returned to the housing of the drug delivery system 100, thereby leaving the cannula in the patient 102. In such embodiments, the cannula may be made of a relatively flexible or soft material, such as plastic, while the introducer member, which may be a solid or hollow needle or trocar, may be made of a relatively rigid or hard material, such as metal. In other embodiments, the cannula may be part of an infusion set to facilitate intravenous administration and may be connected in fluid communication with one or more reservoirs via flexible tubing. In certain such embodiments, the introducer element may be an external applicator or trocar device, and the drug delivery system 100 may be a wearable, portable, or stand-alone infusion system.
[0023] 1 illustrates an embodiment of a drug delivery system 100 including a first dispensing member 110 and a second dispensing member 112. The first dispensing member 110 has a first end connected or connectable in fluid communication with the first reservoir 106 and a second end inserted into the patient 102. Similarly, the second dispensing member 112 has a first end connected or connectable in fluid communication with the second reservoir 108 and a second end inserted into the patient 102. In some embodiments, the second dispensing member 112 may be omitted and the first end of the first dispensing member 110 may be selectively connected in fluid communication with the first reservoir 106 and the second reservoir 108, one at a time, for example via a controllable valve member.
[0024] 1 , the drug delivery system 100 may include a fluid delivery system 114 operable to deliver a first drug product from a first reservoir 106 to a patient via a first dosing member 110 and / or a second drug product from a second reservoir 108 to a patient via a second dosing member 112. The fluid delivery system 114 may store operating energy and / or provide the motive force required to expel the first drug product and / or the second drug product from their respective reservoirs 106 and / or 108. In some embodiments, the fluid delivery system 114 is powered by an external energy source, such as a battery and / or other power source. In other embodiments, the fluid delivery system 114 may itself store operating energy. The fluid delivery system 114 may include a pump (e.g., a peristaltic pump), an electric motor driven plunger, a spring driven plunger (e.g., using a compression spring, an extension spring, a torsion spring, a helical torsion spring, etc.), an osmotic driving force or pressure on the plunger, a pressurizable and releasable gas or liquid source, and a swellable gel, an expandable or balloon-type reservoir with elastic walls that store potential energy when the reservoir is filled with a drug and collapse inward to release the drug when a valve or flow channel is opened, or any combination thereof. Additionally, the fluid delivery system 114 may be controllable to drive the first reservoir 106 independently of the second reservoir 108, or vice versa. In alternative embodiments, multiple fluid delivery systems may be included such that each reservoir may be actuated by its own fluid delivery system.
[0025] The fluid delivery system 114 may operate to continuously deliver the first drug product and / or the second drug product to the patient at a specified flow rate for a specified time (e.g., 10 mL / h for a 24 hour period, 5 mL / h for a 48 hour period, or 0.6 mL / h for a 7 day period) in accordance with the dosing regimen and / or intervention dosing regimen. The delivery rate may depend on various factors, including, but not limited to, physiological factors such as the patient's weight, the patient's body surface, the patient's core temperature, and the severity of a reaction to a particular drug, and / or medical instructions of a healthcare provider. In other embodiments, the fluid delivery system 114 may operate to deliver an entire amount of the first drug product and / or the second drug product as a single bolus to the patient in a relatively short period of time (e.g., seconds, tens of seconds, minutes, tens of minutes, an hour, or several hours).
[0026] With continued reference to FIG. 1 , the drug delivery system 100 may include one or more sensors operable to sense one or more biological conditions of the patient. The one or more sensors may operate continuously throughout the period of drug delivery to provide a real-time measurement of the patient's biological condition. The sensed biological condition may include, for example, a biochemical or analyte level or a change in a biochemical or analyte level. In embodiments in which the likelihood of CRS is monitored, the biochemical may include cytokines, chemokines, and / or other biomarkers indicative of CRS. Such biomarkers include interleukin-1 (IL-1) alpha, IL-1 beta, IL-1 receptor antagonist (IL-1RA), IL-2, IL-3, IL-4, IL-5, IL-6, soluble IL-6 receptor (sIL-6R), IL-7, IL-8, IL-8(HA), IL-10, IL-13, IL-12p70, IL-12 / IL-23p40, IL-15, IL-16, IL-17A, IL-18, IL-22, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), Examples of biochemical proteins that may be bioavailable include, but are not limited to, interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), tumor necrosis factor-β, vascular endothelial growth factor A (VEGF-A), brain-derived neurotrophic factor (BDNF), IP-10, eotaxin, eotaxin-3, monocyte chemoattractant protein-1 (MCP-1), MCP-4, macrophage-derived chemokine (MDC), macrophage inflammatory protein-1 alpha (MIP-1α), MIP-1β, soluble gp130 (sgp130), ferritin, and C-reactive protein (CRP). In some embodiments, one or more sensors may collect or harvest a biological fluid having a biochemical of interest. Such biological fluids may include, for example, blood, plasma, serum, intracellular fluid, intravascular fluid, interstitial fluid, sweat (e.g., eccrine sweat), saliva, tears, urine, and nasal mucosa, or any combination thereof.In addition to, or as an alternative to, sensing biochemical substances, the one or more sensors may be operable to detect or sense one or more other biological conditions of the patient, including, for example, body temperature (e.g., skin temperature, core body temperature, etc.), respiratory rate, heart rate, blood pressure, blood oxygen level, and blood oxygen saturation, or any combination thereof.
[0027] To sense a biological condition of interest, the one or more sensors may use any suitable sensing pathway, including, for example, electrical (e.g., conductivity, etc.), chemical, electrochemical, mechanical (e.g., force), electromechanical, amperometric, potentiometric, piezoelectric, optical (e.g., Raman spectroscopy, infrared spectroscopy, near infrared (NIR) spectroscopy, mid infrared (MIR) spectroscopy, etc.), electrochemiluminescence (e.g., using fluorophores or chromophores), field effect transistor-based biosensing (BioFET) (e.g., immunoFET, DNA-FET, multicolor FRET (mFRET), enzyme field effect transistor, cell potential FET, beetle / chip FET, etc.), Förster resonance energy transfer (FRET), multicolor FRET (mFRET), acoustic (e.g., ultrasonic sensors, etc.), vibrational, temperature (e.g., thermocouples, etc.), fluid pressure, accelerometers, and biometrics (e.g., fingerprints, voice, etc.), or any combination thereof.
[0028] In some embodiments, the one or more sensors may include a probe including, for example, a microneedle, an array of microneedles, a conventional needle (e.g., a syringe needle), a soft cannula, a sweat collector (e.g., with passive sweat collection, active sweat collection by reverse iontophoresis, active sweat collection by cholinergic sweat gland secretory stimulating compounds, etc.), and an optical instrument (e.g., a camera, an interferometer, a photometer, a polarimeter, a reflectometer, a refractometer, a spectrometer, a monochromator, an autocollimator, a surface plasmon resonance-based instrument, etc.), or any combination thereof. In embodiments in which the one or more sensors include an optical instrument, an artificial light source for illuminating or interrogating the biochemical of interest may also be included. In some embodiments, the probe may be temporarily inserted or implanted into the patient's tissue, while in other embodiments, the probe may be placed at or slightly above the skin surface. In preferred embodiments, the one or more sensors include a non-invasive or minimally invasive probe, although invasive sensors are not excluded from this disclosure. Additionally, in some embodiments, the one or more sensors may be incorporated into the dispensing member 110 and / or the dispensing member 112. In certain such embodiments, the dispensing member 110 and / or the dispensing member 112 may include a delivery needle and a wiper may be disposed along the axis of the delivery needle. The wiper may be configured to passively or actively wick blood or other biological fluid along the axis of the delivery needle to a collector where an assay may be performed.
[0029] The one or more sensors may be, but need not be, physically integrated with other components of the drug delivery system 100. In some embodiments, instead of physical integration, the one or more sensors may have only digital integration with the remainder of the drug delivery system 100. In such embodiments, one or more of the sensors may be standalone devices worn by or implanted within the patient and wirelessly communicate digital information with the controller of the fluid delivery system 100 and / or an external computing device, such as the patient's smartphone and / or a remote server.
[0030] In the embodiment shown in FIG. 1, the drug delivery system 100 includes a first sensor 116 and a second sensor 118, each of which is operable to sense a biological condition of the patient. The first sensor 116 may be operable to sense a level of a biochemical substance or a change in the level of a biochemical substance, and the second sensor 118 may be operable to sense the patient's core body temperature and / or skin temperature, although the first sensor 116 and the second sensor 118 are not limited to such sensing functions and may be operable to sense any of the biological conditions mentioned herein and others. In this embodiment, the biochemical substances sensed by the first sensor 116 may include cytokines and / or biomarkers indicative of CRS. In alternative embodiments, either the first sensor 116 or the second sensor 118 may be omitted.
[0031] The drug delivery system 100 may further include a controller 120 configured to control the operation of various components of the drug delivery system 100, including the fluid delivery system 114 and the output unit 122. Additionally, the controller 120 may be configured to receive and / or process information, data, signals (analog and / or digital), or other output from the first sensor 116, the second sensor 118, and / or other components of the fluid delivery system 100, or from external components, such as the external computing device 104. Additionally, the controller 120 may be responsive to outputs received from such components and may be configured to automatically control the operation of certain components, such as the fluid delivery system 114 and / or the output unit 122, in accordance with programming or other configurations of the controller 120.
[0032] Controller 120 may include and / or perform its operations via electrical devices (e.g., hardwired circuitry, a microprocessor, etc.), a combination of electrical devices, a mechanical device, a combination of mechanical devices, a chemical device, a combination of chemical devices, or any combination thereof (e.g., electromechanical devices, electrochemical devices, etc.). According to embodiments in which controller 120 includes a microprocessor or the like, the configuration of controller 120 may correspond to software or other programming of controller 120. In some embodiments, controller 120 may be pre-configured by a manufacturer and / or healthcare provider such that it cannot be later reconfigured by a patient or other end user, while in other embodiments controller 120 may be configurable within the bounds of common sense by any individual or entity.
[0033] In some embodiments, the controller 120 may be provided as a computing device including one or more processors and one or more memories in communication with or integrated with each other. The one or more processors may include, for example, one or more of a microprocessor, a microcontroller, a programmable logic controller, a digital signal processor, a microcomputer, a central processing unit, a field programmable gate array, a logic circuit, an analog circuit, a digital circuit, a software-based processing module, and any device that manipulates signals (analog and / or digital) based on hard-coding of circuitry and / or operational instructions, or any combination thereof. The one or more memories may include, for example, a non-transitory computer-readable storage medium configured to store data including non-transitory computer-readable instructions that make up one or more services, programs, and / or modules, as well as any data operated on or generated by such services, programs, and / or modules. The memory may store data on a volatile memory (e.g., a random access memory (RAM), etc.) and / or a non-volatile memory (e.g., a hard disk), and may be a removable or non-removable memory. The one or more processors may be configured to retrieve and execute instructions stored in one or more memories to perform or implement various functions of the drug delivery system 100, including, for example, operating the fluid delivery system 114 to deliver a first drug product and / or a second drug product to a patient according to a dosing regimen and / or an interventional dosing regimen.
[0034] In some embodiments, the controller 120 may be communicatively coupled (e.g., via a wired or wireless connection) with one or more of the external computing device 104, the fluid delivery system 114, the first sensor 116, the second sensor 118, and the output unit 122 such that the controller 120 may send communications to and / or receive communications from one or more of the external computing device 104, the fluid delivery system 114, the first sensor 116, the second sensor 118, and the output unit 122. Such communications may be electrical and / or mechanical in nature and / or may include information, data, and / or signals (analog and / or digital).
[0035] According to some embodiments, the controller 120 may operate the fluid delivery system 114 to deliver a first drug product held in the first reservoir 106 to the patient in accordance with a dosing regimen for which the controller 120 is configured. Over the course of the regimen, the controller 120 may be configured to operate the fluid delivery system 114 to interrupt, terminate, or inhibit (e.g., reduce or prevent) delivery of the first drug product to the patient in response to a determination that (i) a biological condition sensed by the first sensor 116 is within or outside a first predetermined range of values, or is above or below a first predetermined value, and / or (ii) a biological condition sensed by the second sensor 118 is within or outside a second predetermined range of values, or is above or below a second predetermined value. Additionally or alternatively, as part of the interventional dosing regimen, the controller 120 may be configured to operate the fluid delivery system 114 to initiate delivery of the second drug product held in the second reservoir 108 to the patient in response to a determination that (i) and / or (ii) are met. Still further, the controller may be configured to operate the output unit 122 to notify the patient and / or a healthcare provider in response to a determination that (i) and / or (ii) are met. As used herein, a "predetermined value range" includes a fixed value range, as well as values generated by a formula or algorithm according to one or more variables or inputs that may be determined by the patient's disease state, such as, for example, baseline disease burden, prior to infusion of the first drug product.
[0036] It should be noted that although the controller 120 may be configured to analyze the output (e.g., signals, data, information, etc.) received from the first sensor 110 and / or the second sensor 112 and make a determination as to whether (i) and / or (ii) are satisfied based on this analysis, the controller 120 need not be responsible for this analysis and determination. For example, an external computing device may be responsible for analyzing the output from the first sensor 110 and / or the second sensor 112 and then communicate its determination regarding (i) and / or (ii) to the controller 120.
[0037] The output unit 122 may be any device suitable for conveying information to a patient or user, including a display (e.g., a liquid crystal display), a touch screen, a light (e.g., a light emitting diode), a vibrator (e.g., an electromechanical vibration element), a mechanical or color changing flag member, a speaker, an alarm, and / or any other suitable device.
[0038] FIG. 2 illustrates a method 200 of operating a drug delivery system, such as the drug delivery system 100 of FIG. 1, to sense various biological conditions of the patient 102 and automatically control the drug delivery system 100 according to these sensed biological conditions so that an interventional dosing regimen can be implemented with minimal or no input from a healthcare provider. A brief review of the flow chart of FIG. 2 will show that the method 200 according to FIG. 2 illustrates the determination of various biological conditions of the patient 102 and actions taken in response to or in relation to these conditions. It should also be understood that while the method 200 includes certain decisions and actions, other embodiments of a method of operating a drug delivery system according to the present disclosure may include only some of the decisions and actions described in connection with FIG. 2 and / or may include additional decisions and actions. Furthermore, while the method 200 is directed to CRS interventions involving supportive care and / or infusion of anti-cytokine agents, it should be understood that the general principles associated with the method are applicable to a wide range of interventional dosing procedures in a variety of settings.
[0039] The method 200 may begin at block 202 with the infusion of a first drug product comprising an immunotherapeutic agent. In some embodiments, the immunotherapeutic agent may comprise a bispecific T cell-enhancing (e.g., BiTE®) antibody construct (e.g., blinatumomab) or a CAR-T cell receptor (e.g., anti-CD19 CAR-T cell). The first drug product may be delivered to the patient 102 by automatically operating the fluid delivery system 114 by the controller 120 to expel the first drug product from the first reservoir 106 to the patient 102 via the first administration member 110. Prior to drug delivery, the first administration member 110 may be inserted into the patient 102, for example, to be in fluid communication with a vein or body cavity, subcutaneous tissue, or the like. In some embodiments, the fluid delivery system 100 may include an insertion mechanism for automatically inserting the first administration member 110 at the injection site upon initiation by the patient or a healthcare provider. In certain such embodiments, the housing of the insertion mechanism or the entire drug delivery system may be adhered to the patient's skin as a preliminary step. In other embodiments, the first administration member 110 may be manually inserted at the injection site.
[0040] The controller 120 may be configured (e.g., pre-configured) by the patient 102, a healthcare provider, or a device manufacturer to control the fluid delivery system 114 to infuse the first drug product to the patient 102 at a specified flow rate and / or continuously for a specified time according to a predetermined dosing regimen. In some embodiments, this may involve infusing the first drug product at about (e.g., ±10%) 10 mL / h for a 24 hour period, or at about (e.g., ±10%) 5 mL / h for a 48 hour period, or at about (e.g., ±10%) 0.6 mL / h for a 7 day period, or any other suitable flow rate and / or duration. According to some embodiments, a particular delivery rate may not be specified and the controller 120 may simply be set to a particular time period during which drug delivery will occur, including, for example, a period of minutes, tens of minutes, an hour, or hours (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 36, or 48 hours, or fractions thereof such as 22.5 hours). In yet another embodiment, neither a particular rate nor a particular time period may be configured in the controller 120, and instead the controller 120 may simply activate or release an energy source (e.g., a spring or source of pressurized gas or fluid) that naturally expels the first drug product from the first reservoir 106 over a general time frame that may vary depending on environmental factors such as back pressure, temperature, drug viscosity, etc. In embodiments where the fluid delivery system 100 is not portable and / or the duration of drug delivery is very long, the patient may have the ability to interrupt the delivery of the first drug product via the controller 120 or otherwise so that the patient can take a break for essentials such as eating, sleeping, etc.
[0041] One or more sensors may be configured to sense one or more biological conditions of the patient 102 simultaneously with, immediately before, or immediately after the infusion of the first drug product begins. The biological conditions may be sensed continuously or intermittently throughout the duration of the method 200. Depending on the sensor, the sensor may be placed in contact with the surface of the patient's skin, removably attached (e.g., glued) to the surface of the patient's skin, inserted into the patient (e.g., inserted into the subcutaneous tissue of the patient, inserted into the digestive tract, etc.), implanted within the patient, or placed within a short distance from the patient. In this embodiment, the first sensor 116 may be inserted into the patient's tissue to sense the level of cytokines or changes in the level of cytokines in the patient 102 (see block 204 of FIG. 2), and the second sensor 118 may be placed in contact with the surface of the patient's skin to sense the patient's body temperature (see block 206 of FIG. 2). In embodiments in which the first sensor 116 is incorporated into the first delivery member 110, insertion of the first sensor 116 into the patient may be accomplished by insertion of the first delivery member 110 into the patient. In alternative embodiments, the first sensor 116 may not be inserted into the patient, but rather may be placed on the surface of the patient's skin to collect sweat (e.g., eccrine sweat) and detect cytokine levels or changes in cytokine levels in the collected sweat. Furthermore, in certain embodiments, the first sensor 116 or the second sensor 118 may be omitted. Still further, in some embodiments, the first sensor 116 and the second sensor 118 may be physically integrated with each other into a single unit.
[0042] The method 200 then proceeds to block 208, where a determination is made whether the patient 102 is exhibiting symptoms or signs of CRS. The determination may be based on whether (i) the biological condition sensed by the first sensor 116 is within or outside a first predetermined range of values, or above or below a first predetermined value, and / or (ii) the biological condition sensed by the second sensor 118 is within or outside a second predetermined range of values, or above or below a second predetermined value. In the preceding sentence and elsewhere throughout this disclosure, the use of "and" in "and / or" suggests that both (i) and (ii) must be met for the patient to be determined to be exhibiting signs of CRS. Meanwhile, the "or" in "and / or" suggests that only one of (i) or (ii) must be met for the patient to be determined to be exhibiting signs of CRS. Additional and / or alternative conditions or factors may be evaluated to determine whether the patient is exhibiting signs of CRS. Further, in some embodiments, the determination at block 208 may be accomplished by reference to a database, look-up table, and / or algorithm, which may be stored in the memory of the controller 120 or elsewhere.
[0043] In some embodiments, the determination at block 208 may be accomplished by receiving an output (e.g., information, data, signals, etc.) from the first sensor 116 and / or the second sensor 118 at the controller 120 and then analyzing the output at the controller 120 to determine whether (i) and / or (ii) are met. However, in alternative embodiments, the controller 120 may not be involved in this determination. Instead, for example, an external computing unit (e.g., the external computing unit 104) may receive an output from the first sensor 116 and / or the second sensor 118 (e.g., received directly or indirectly from the sensor via wired or wireless communication) and then analyze the output to determine whether (i) and / or (ii) are met. The external computing unit may then inform the controller 120 of its determination (e.g., via wired or wireless communication), and the controller 120 may take appropriate action based on the determination.
[0044] If it is determined in block 208 that a CRS intervention is not required, the method 200 may continue infusing the first drug product and continue monitoring one or more biological conditions of the patient 102 (see block 210). On the other hand, if it is determined in block 208 that a CRS intervention is required or recommended, the method 200 may proceed to block 212. In block 212, the controller 120 may operate the fluid delivery system 114 to interrupt or inhibit delivery of the first drug product to the patient, according to its programming or other configuration. In some embodiments, the controller 120 may also control the output unit 122 at this stage to notify the patient and / or the healthcare provider (e.g., by visual and / or audio output) that symptoms of CRS have been detected and / or that administration of the first drug product has been interrupted or inhibited as a result. Additionally or alternatively, the controller 120 may send a signal to an external computing device 104, which may function as an output unit, so that a remote healthcare provider, family member, friend, and / or other individual or entity may be notified via the external computing device 104 that the patient 102 is experiencing symptoms of CRS.
[0045] As an alternative to having the controller 120 automatically suspend or inhibit delivery of the first drug product in block 212, delivery of the first drug product may be manually stopped by the patient 102 and / or a healthcare provider after receiving notification of the onset of CRS via the output unit 122, the external computing device 104, and / or another device.
[0046] After or simultaneously with the actions in block 212, a determination may be made as to whether administration of an anti-cytokine agent is necessary to treat the symptoms of CRS (see block 214 in FIG. 2). This determination may be made by the controller 120 or another device, such as the external computing unit 104. Furthermore, this determination may be based on the degree or extent to which (i) the biological condition sensed by the first sensor 116 is within or outside a first predetermined range of values, or is above or below a first predetermined value, and / or (ii) the biological condition sensed by the second sensor 118 is within or outside a second predetermined range of values, or is above or below a second predetermined value. Additional and / or alternative conditions or factors may also be evaluated in block 214.
[0047] If it is determined in block 214 that administration of an anti-cytokine agent is unnecessary, the method 200 may proceed to block 218. Here, the healthcare provider and / or patient may be instructed to provide supportive care without administration of an anti-cytokine agent to mitigate the effects of CRS. This instruction, which may be generated by the controller 120, may be communicated to the healthcare provider and / or patient via the output unit 122 and / or the external computing device 104. This instruction may be visual, audio, and / or any other form of communication. In some embodiments, the supportive care may include administering an antipyretic product and / or IV fluids to the patient 102 intravenously or otherwise. This administration step may be performed manually in some embodiments and / or may not involve the drug delivery system 100. However, in other embodiments, the fluid delivery system 100 may include one or more reservoirs containing an antipyretic product and / or IV fluid, and the controller 120 may automatically operate the fluid delivery system 114 to deliver the antipyretic product and / or IV fluid to the patient via a dispensing member (including, but not limited to, the first dispensing member 110, the second dispensing member 112, or another dispensing member).
[0048] While supportive care is provided in block 218, one or more sensors may continue to monitor one or more biological conditions of the patient. Then, after a predetermined period of time, a decision may be made as to whether infusion of the first drug product can be resumed, for example in light of the fact that the symptoms of CRS have subsided (see block 220). This decision may be made by the controller 120 or another device, such as the external computing unit 104. Moreover, this decision may be similar to the decision made in block 208, except in reverse. In block 218, additional and / or alternative conditions or factors may be evaluated.
[0049] If resumption of delivery of the first drug product is determined to be appropriate in block 220, the controller 120 may automatically control the fluid delivery system 114 to resume delivery of the first drug product from the first reservoir 106 to the patient 102. The method 200 may then begin again from the beginning. In contrast, if the determination in block 220 was that resumption of delivery of the first drug product is not appropriate, the controller 120 may terminate or prevent any additional delivery of the first drug product to the patient 102, and the method 200 may be terminated.
[0050] Returning to block 214, if administration of an anti-cytokine agent is determined to be necessary at block 214, the method 200 may proceed to block 216, where the controller 120 may terminate any additional delivery of the first drug product to the patient 102. In an alternative embodiment, at block 216, the controller 120 may simply pause or inhibit delivery of the first drug product to the patient.
[0051] The method 200 may then proceed to block 226 where delivery of a second drug product from the second reservoir 108 to the patient 102 may begin. The second drug product may treat CRS or another condition or syndrome induced by administration of the first drug product. In some embodiments, the second drug product may include an anti-cytokine agent. The anti-cytokine agent may include, for example, a corticosteroid (e.g., dexamethasone), an anti-interleukin-6 (IL-6) receptor antibody (e.g., tocilizumab), and / or an anti-IL-6 chimeric monoclonal antibody (e.g., siltuximab). The second drug product may be delivered to the patient 102 by automatically operating the fluid delivery system 114 by the controller 120 to expel the second drug product from the second reservoir 108 to the patient 102 via the second administration member 112. Prior to the start of the method 200 or immediately prior to block 226, the second dispensing member 112 may be inserted into the patient 102, e.g., into fluid communication with a vein or body cavity, subcutaneous tissue, etc. In some embodiments, the fluid delivery system 100 may include an insertion mechanism for automatically inserting the second dispensing member 112 at the injection site upon initiation by the patient or healthcare provider. In certain such embodiments, the housing of the insertion mechanism or the entire drug delivery system may be adhered to the patient's skin as a preliminary step. In other embodiments, the second dispensing member 112 may be manually inserted into the vein or at the injection site.
[0052] In yet another alternative embodiment, the second drug product may be delivered to the patient 102 via the first dispensing member 110. In such an alternative embodiment, the controller 120 may control the valve member such that the first dispensing member 110 is in fluid communication with the second reservoir 108 rather than the first reservoir 106 prior to delivery of the second drug product.
[0053] The controller 120 may be configured (e.g., pre-configured) by the patient 102, a healthcare provider, or a device manufacturer to control the fluid delivery system 114 to infuse the second drug product to the patient 102 at a specified flow rate and / or continuously for a specified time according to a predetermined dosing regimen. In some embodiments, this may involve infusing the second drug product at about (e.g., ±10%) 10 mL / h for about (e.g., ±10%) a 2 hour period, or at about (e.g., ±10%) 5 mL / h for about (e.g., ±10%) a 4 hour period, or any other suitable flow rate and / or duration. According to some embodiments, a particular delivery rate may not be specified and the controller 120 may simply be set to a particular time period during which the delivery of the second drug product will occur, including, for example, a period of minutes, tens of minutes, an hour, or hours (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 36, or 48 hours, or fractions thereof such as 22.5 hours). In yet another embodiment, neither a particular rate nor time period may be configured in the controller 120, and instead the controller 120 may simply activate or release an energy source (e.g., a spring or source of pressurized gas or fluid) that naturally expels the second drug product from the second reservoir 108 over a general time frame that may vary depending on environmental factors such as back pressure, temperature, drug viscosity, etc. In embodiments in which the fluid delivery system 100 is not portable and / or the period of delivery of the second drug product is very long, the patient may have the ability to interrupt the delivery of the second drug product via the controller 120 or otherwise so that the patient can take a break for essentials such as eating, sleeping, etc.
[0054] The above method advantageously provides for automated detection and treatment of CRS or other syndromes or conditions induced by administration of a drug product, which may lead to earlier identification of CRS or other syndromes or conditions, thereby increasing the likelihood that the treatment can be successful, and further reduces the burden on healthcare providers to monitor patients for side effects such as CRS after drug treatment.
[0055] It should be understood that, according to other embodiments of the present disclosure, various aspects of method 200 described in connection with Figure 2 may be considered optional or omitted. For example, it may not be necessary to make a determination as to whether an anti-cytokine agent should be administered at block 214. If this determination at block 214 is omitted, the method proceeds directly from block 208 to block 216 if it is determined at block 208 that a CRS intervention is required.
[0056] Referring now to Figure 3, an on-body injector implementation of the drug delivery system 100 described above is described. Various elements of the on-body injector shown in Figure 3 are similar in function to elements of the drug delivery system 100 shown in Figure 1. In Figure 3, these elements are assigned the same reference numbers as in Figure 1, except that in Figure 3, 200 has been added. The description of some of these elements has been simplified or eliminated for the sake of brevity. Additionally, the on-body injector shown in Figure 3 may be used in accordance with the method 200 described in connection with Figure 2.
[0057] 3 illustrates an on-body injector 300 that includes an insertion mechanism 305, a first reservoir 306, a second reservoir 308, a fluid pathway connection assembly 307, a fluid delivery system 314, and a controller 320, each of which may be disposed within an interior space of a main housing 329. An actuator 328 (e.g., a user-depressible button, a touch screen, a microphone, etc.) may protrude from or be otherwise disposed on an exterior surface of the housing 329 and may be configured to initiate operation of the on-body injector 300 by activating the insertion mechanism 305, the fluid pathway connection assembly 307, the fluid delivery system 314, the controller 320, and / or other mechanisms and / or electronics by mechanical and / or electrical means (shown in dashed lines in FIG. 3 ). In embodiments in which the actuator 328 is a button that is pressed or otherwise physically actuated by a user or patient, the actuator 328 may be configured to exert the motive force necessary to activate the insertion mechanism 305, the fluid pathway connection assembly 307, the fluid delivery system 314, the controller 320, and / or other elements. In such embodiments, the actuator 328 may be physically connected, directly or indirectly via a mechanical linkage, to the insertion mechanism 305, the fluid delivery system 314, the fluid pathway connection assembly 307, and / or other elements such that manually pressing or otherwise interacting with the actuator 328 provides the motive force necessary to activate the insertion mechanism 305, the fluid pathway connection assembly 307, the fluid delivery system 314, and / or other elements. For example, in some embodiments, manually pushing the actuator 328 may move the fluid pathway connection assembly 307 toward the stationary reservoirs 306 and 308, or alternatively, move the movable reservoirs 306 and 308 toward the stationary fluid pathway connection assembly 307, thereby causing the container access needles to pierce the respective sealing members and enter the respective drug-containing chambers of the reservoirs 306 and 308.Additionally or alternatively, the actuator 328 may operate as an input device that transmits electrical and / or mechanical signals to the controller 320, which may further execute programmable instructions to control the operation of the insertion mechanism 305, the fluid delivery system 314, the fluid pathway connection assembly 307, and / or other elements. In such an embodiment, the controller 320 may include a processor (e.g., a microprocessor) and non-transitory memory for storing the programmable instructions executed by the processor. Furthermore, in such an embodiment, the fluid delivery system 314 may be separate from the actuator 328 and may include an internal actuator (e.g., an electric motor, a pneumatic or hydraulic pump, and / or a source of pressurized gas or liquid) that exerts the motive force necessary to activate the insertion mechanism 305, the fluid pathway connection assembly 307, the fluid delivery system 314, and / or other elements in response to electrical control signals received from the controller 320.
[0058] 3, the housing 329 may include a bottom wall 325 configured to be removably attached (e.g., adhered by an adhesive) to the patient's skin 311, and a top wall 327 including a window 335 for viewing the output unit 322 (e.g., visual and / or audio indicators such as lights, graphical displays, speakers, etc.) and / or the reservoirs 306 and 308. An opening 331 may be formed in the bottom wall 325, and optionally a pierceable sterile barrier 333, such as a pierceable septum, may extend across the opening 331 to seal the interior of the housing 329 prior to use. In some embodiments, the pierceable sterile barrier 333 may be omitted, and instead a removable sealing member (not shown) may cover and seal the opening 331 prior to use.
[0059] After the bottom wall 325 of the housing 329 is attached to the patient's skin 311, the insertion mechanism 305 may be actuated to move the delivery member 310, in this case including the cannula 323, from a retracted position within the housing 329 to a deployed position extending outside the housing 329. In this embodiment, this may involve the insertion mechanism 305 inserting the trocar or introducer member 321 and the cannula 323 surrounding the introducer member 321 through a pierceable sterile barrier 333 into the patient's tissue, as shown in FIG. 3. Immediately or shortly thereafter, the insertion mechanism 305 may automatically retract the introducer member 321, leaving the distal open end of the cannula 323 inside the patient for subcutaneous delivery of the first and second drug products from the reservoirs 306 and 308, respectively. The introducer member 321 may be solid and have a sharp end for piercing the patient's skin 311. Additionally, the introducer member 321 may be made of a more rigid material than the cannula 323. In some embodiments, the introducer member 321 may be metallic and the cannula 323 may be made of plastic or another polymer. The relative flexibility of the cannula 323 may allow the cannula 323 to be subcutaneously positioned within the patient's tissue for a period of time without causing pain or significant discomfort to the patient. In other embodiments (not shown), the introducer member 321 and cannula 323 may be omitted and instead the insertion mechanism 305 may insert only a rigid hollow needle into the patient for subcutaneous delivery of the drug product.
[0060] In some embodiments, the insertion mechanism 305 may include one or more springs (e.g., compression springs, extension springs, torsion springs, helical torsion springs, etc.) that are initially held in a biased state and released upon depression of the actuator 328 to insert the introducer member 321 and cannula 323 or rigid hollow needle into the patient. Additionally, retraction of the introducer member 321 may be accomplished by automatic release of another spring after the introducer member 321 and cannula 323 have been inserted into the patient. Other power sources for insertion and / or retraction are also contemplated, including, for example, an electric motor, a hydraulic or pneumatic pump, or a canister that releases pressurized gas or liquid to provide the actuation energy.
[0061] 3, the first reservoir 306, which may be referred to in some contexts as a primary container, may include a wall 338a having an interior surface and an exterior surface that define an interior space that is or can be filled with a first drug product. In some embodiments, the first reservoir 306 may be pre-filled with the first drug product by a drug manufacturer prior to mounting the first reservoir 306 on the on-body injector 300. In some embodiments, the first reservoir 306 may be rigidly connected to the housing 329 such that the first reservoir 306 cannot move relative to the housing, while in other embodiments, the first reservoir 306 may be slidably connected to the housing 329 such that the first reservoir 306 can move relative to the housing 329 during operation of the on-body injector 300. The first reservoir 306 may have an elongated barrel-like or cylindrical shape extending along a longitudinal axis A1. In some embodiments, the longitudinal axis A1 of the first reservoir 306 may be perpendicular, or substantially perpendicular, or otherwise non-parallel to the direction in which the insertion mechanism 305 inserts the dispensing member 310 into the patient. This configuration may allow the on-body injector to have a generally flat, low-profile shape that can be worn by the patient without impeding the patient's movement. First, a stopper 334a or other plunger member may be disposed within the first reservoir 306 at the proximal end 336a of the first reservoir 306. The stopper 334a may sealingly and slidably engage an inner surface of the wall 338a of the first reservoir 306 and may be movable relative to the wall 338a of the first reservoir 306.
[0062] The second reservoir 308 may be configured similarly to the first reservoir 306. Similar components are designated with a "b" suffix instead of the "a" suffix in FIG. 3 for the second reservoir 308.
[0063] In the illustrated embodiment, the first reservoir 306 and the second reservoir 308 are stacked vertically on one another, however, in alternative embodiments, the first reservoir 306 and the second reservoir 308 may be disposed on a common horizontal plane to limit the height of the on-body injector.
[0064] The amount of the first drug product contained in the first reservoir 306 or the amount of the second drug product contained in the second reservoir 308 can be any amount within the range of about (e.g., ±10%) 0.5 to 100 mL, or any amount within the range of about (e.g., ±10%) 0.5 to 50 mL, or any amount within the range of about (e.g., ±10%) 0.5 to 25 mL, or any amount within the range of about (e.g., ±10%) 0.5 to 10 mL, or any amount within the range of about (e.g., ±10%) 1 to 10 mL, or any amount within the range of about (e.g., ±10%) 1 to 8 mL. The volume may be any amount within the range of about (e.g., ±10%) 1-5 mL, or any amount within the range of about (e.g., ±10%) 1-3 mL, or any amount of about (e.g., ±10%) 3 mL or more, or any amount of about (e.g., ±10%) 10 mL or more, or any amount of about (e.g., ±10%) 25 mL or more, or any amount of about (e.g., ±10%) 50 mL or more, or any amount of about (e.g., ±10%) 60 mL or more, or any amount of about (e.g., ±10%) 75 mL or more.
[0065] During operation of the on-body injector 300, the fluid delivery system 314 may selectively push the stoppers 334a and 334b along their respective longitudinal axes A1 and A2 from the proximal end 336a or 336b to the distal end 337a or 337b of their respective reservoirs to expel the first and second drug products one at a time from their respective reservoirs. In alternative embodiments, the fluid delivery system 314 may be configured to simultaneously push the stoppers 334a and 334b to expel the first and second drug products simultaneously. In some embodiments, the fluid delivery system 314 may include one or more springs (e.g., a compression coil spring, an extension coil spring, a torsion coil spring, a helical torsion spring, etc.) that are initially held in a biased state and released upon pressing the actuator 328 and / or another actuator. Upon release, the spring may expand or contract, moving stopper 334a and stopper 334b within their respective reservoirs and expelling the drug product contained therein. In other embodiments, the fluid delivery system 314 may include an electric motor that rotates a gear mechanism, including, for example, one or more sprocket gears, to cause axial movement of stopper 334a and stopper 336b within their respective reservoirs. In yet another embodiment, the fluid delivery system 314 may include both an electric motor and a spring, where the electric motor regulates the extension of the spring via a tether or pulley system. In yet another embodiment, the fluid delivery system 314 may include a canister that releases pressurized gas or liquid to provide the actuation energy.
[0066] At the tip 337a or tip 337b of each reservoir, an opening may be formed in the tip surface of the wall 338a or wall 338b. The tip surface may define an exterior surface or a portion of the wall 338a or wall 338b. Prior to operation of the on-body injector 300, the opening may be covered and sealed by a seal member 340a or seal member 340b, such as a pierceable septum, connected to the tip 337a or tip 337b of each reservoir. In general, the seal member 340a and seal member 340b may be configured to selectively allow access to the reservoirs 306 and 308, respectively. During operation, the seal member 340a and seal member 340b may be physically altered (e.g., pierced) to allow fluid communication with the first and second drug products in the reservoirs 306 and 308. In some embodiments, seal member 340a and seal member 340b may be made of a flexible or elastically deformable material, such as rubber, that can be penetrated or pierced by the sharp end, i.e., tip 363a or 363b, of vessel access needle 360a or vessel access needle 360b, respectively, of fluid pathway connection assembly 307.
[0067] 3, the fluid pathway connection assembly 307 may be configured to selectively establish fluid communication between the reservoir 306 or reservoir 308, respectively, and the insertion mechanism 305 via the sterile fluid flow path during use of the on-body injector 300. Prior to use of the on-body injector 300, the fluid pathway connection assembly 307 may not be in fluid communication with either the reservoir 306 or the reservoir 308. During set-up of the on-body injector 300 or during operation of the on-body injector 300 but prior to drug delivery, the necessary connections may be enabled, connected, or opened manually by a user or automatically by the on-body injector 300 while establishing fluid communication between the fluid pathway connection assembly 307 and the first reservoir 306 and / or the second reservoir 308. The fluid delivery system 314 may then selectively move stoppers 334a and 334b in a distal direction to selectively push the first drug product and the second drug product through the sterile fluid flow path of the fluid pathway connection assembly 307 and into the cannula 333 or needle or other administration member for subcutaneous delivery to the patient.
[0068] The fluid pathway connection assembly 307 may include a first end 344 selectively connected in fluid communication to the first and second reservoirs 306 and 308, a second end 348 connected in fluid communication to the insertion mechanism 305, and a fluid passageway 350 providing fluid communication between the first and second ends 344 and 348. The fluid passageway 350 may be sterile and may be made partially or completely from flexible tubing 352. There may be slack in the flexible tubing 352 initially to allow the fluid pathway connection assembly 307 to move relative to the housing 329 and / or to allow components of the insertion mechanism 305 to which the fluid pathway connection assembly 307 is attached to move relative to the housing 329.
[0069] 3, the first end 344 of the fluid pathway connection assembly 307 may include a first vessel access needle 360a and a second vessel access needle 360b. Prior to activation of the fluid pathway connection assembly 307, the vessel access needles 360a and 360b may be held in a retracted position (as seen in FIG. 3) in which the proximal ends of the vessel access needles 360a and 360b are disposed externally and thus not in fluid communication with the first reservoir 306 and the second reservoir 308, respectively. During operation of the fluid pathway connection assembly 307, the first vessel access needle 360a may move toward the first reservoir 306 to an operative position in which the proximal end of the first vessel access needle 360a is in fluid communication with the first reservoir 306. Concurrent with this action, or at a later time during use of the on-body injector 300, the fluid pathway connection assembly 307 may move the second container access needle 360b toward the second reservoir 308 to an operative position in which a proximal end of the second container access needle 360b is in fluid communication with the second reservoir 308. The fluid delivery system 314 may then move the stopper 334a and / or stopper 334b in a distal direction to expel the first drug product and / or the second drug product held in the reservoir through each container access needle 360a and container access needle 360b, then through the sterile fluid flow path of the fluid pathway connection assembly 307, and then into the cannula 323 or needle or other administration member of the insertion mechanism 305 for subcutaneous delivery to the patient.
[0070] In some embodiments, the fluid pathway connection assembly 307 may include a valve member 380 actuable by the controller 320 to selectively allow fluid communication between the first vessel access needle 360a and the fluid passageway 350, or alternatively, between the second vessel access needle 360b and the fluid passageway 350.
[0071] The on-body injector 300 may also include one or more sensors operable to sense one or more biological conditions of the patient. The one or more sensors may be any of those described above in connection with the drug delivery system 100 or other types of sensors. In the embodiment shown in FIG. 3, the first sensor 316 and the second sensor 318 are disposed on the bottom wall 325 of the housing 329. The first sensor 316 includes an array of microneedles insertable into the patient's skin 311, and the second sensor 318 includes a thermocouple or a biochemical sensor (e.g., a skin or sweat sensor) positioned in contact with but not penetrating the surface of the patient's skin 311. Other configurations of the first sensor 316 and the second sensor 318 are possible. The first sensor 316 may be operable to detect a level of a biochemical substance or a change in the level of a biochemical substance, and the second sensor 318 may be operable to detect a patient's core body temperature, skin temperature, and / or a level of a biochemical substance or a change in the level of a biochemical substance, although the first sensor 316 and the second sensor 318 are not limited to such detection functions and may be operable to detect any of the biological conditions mentioned herein and others. In this embodiment, the biochemical substances detected by the first sensor 316 may include cytokines, chemokines, and / or other biomarkers indicative of CRS. In alternative embodiments, either the first sensor 116 or the second sensor 118 may be omitted. Additionally, sensors may also be included depending on the biological condition to be monitored.
[0072] Except where other structural or configuration differences are required, the on-body injector 300 shown in FIG. 3 may operate similarly to the drug delivery system 100 described above and / or may be used to implement the interventional dosing regimen described in connection with the method 200 of FIG. 2 or certain portions thereof.
[0073] As will be appreciated, the systems, devices, and methods according to the present disclosure may have one or more advantages over the prior art, any one or more of which may be present in a particular embodiment in accordance with the features of the present disclosure included in that embodiment. Other advantages not specifically described herein may be recognized as well.
[0074] Drug Information In the above description, various assemblies, devices, and methods are described for use with drug delivery devices. It should be clear that the assemblies, drug delivery systems or devices, or methods can further include the use of the following drugs, but note that the following list should not be considered exhaustive or limiting. The drugs are placed in a reservoir. In some cases, the reservoir is a primary container that is filled or pre-filled with drugs for treatment. The primary container can be a cartridge or a pre-filled syringe, or a non-rigid collapsible pouch such as an IV bag.
[0075] For example, the drug delivery device, or more specifically, the reservoir of the device, may be loaded with colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF). Such G-CSF agents include, but are not limited to, Neupogen® (filagrastim) and Neulasta® (pegfigrastim). In various other embodiments, the drug delivery device may be used with various pharmaceutical agents, such as erythropoietin stimulating agents (ESAs), which may be in liquid or lyophilized form.ESAs include Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa), Dynepo® (epoetin delta), Mircera® (methyoxy polyethylene glycol epoetin beta), Hematide®, MRK-2578, INS-22, Retacrit® (epoetin zeta), Neorecormon® (epoetin beta), Silapo®, and others. any molecule that stimulates erythropoiesis, such as epoetin zeta, Binocrit® (epoetin alfa), epoetin alfa Hexal, Abseamed® (epoetin alfa), Ratioepo® (epoetin theta), Eporatio® (epoetin theta), Biopoin® (epoetin theta), epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, and epoetin delta, and The following patents or patent applications, each of which is incorporated herein by reference in its entirety: U.S. Pat. No. 4,703,008; U.S. Pat. No. 5,441,868; U.S. Pat. No. 5,547,933; U.S. Pat. No. 5,618,698; U.S. Pat. No. 5,621,080; U.S. Pat. No. 5,756,349; U.S. Pat. No. 5,767,078; U.S. Pat. No. 5,773,569; U.S. Pat. No. 5,955,422; U.S. Pat. No. 5,986,047; Nos. 6,583,272, 7,084,245, and 7,271,689, and PCT Publication Nos. WO 91 / 05867, WO 95 / 05465, WO 96 / 40772, WO 00 / 24893, WO 01 / 81405, and WO 2007 / 136752, or variants or analogs thereof.
[0076] The ESA may be an erythropoiesis stimulating protein. As used herein, "erythropoiesis stimulating protein" refers to any protein that directly or indirectly causes the activation of the erythropoietin receptor, for example, by binding to the receptor and causing receptor dimerization. Erythropoiesis stimulating proteins include erythropoietin and its variants, analogs, or derivatives that bind to and activate the erythropoietin receptor; antibodies that bind to and activate the erythropoietin receptor; or peptides that bind to and activate the erythropoietin receptor. Erythropoiesis stimulating proteins include, but are not limited to, epoetin alpha, epoetin beta, epoetin delta, epoetin omega, epoetin iota, epoetin zeta, and analogs thereof, PEGylated erythropoietin, carbamylated erythropoietin, mimetic peptides (including EMP1 / Hematide), and mimetic antibodies. Exemplary erythropoiesis stimulating proteins include erythropoietin, darbepoietin, erythropoietin agonist variants, and peptides or antibodies that bind to and activate the erythropoietin receptor (as well as the compounds reported in U.S. Patent Application Publication Nos. 2003 / 0215444 and 2006 / 0040858, the disclosures of each of which are incorporated herein by reference in their entireties), as well as the following patents or patent applications, the disclosures of which are each incorporated herein by reference in their entireties: U.S. Pat. No. 4,703,008; U.S. Pat. No. 5,441,868; U.S. Pat. No. 5,547,933; U.S. Pat. No. 5,547,933; Patent No. 5,618,698, U.S. Patent No. 5,621,080, U.S. Patent No. 5,756,349, U.S. Patent No. 5,767,078, U.S. Patent No. 5,773,569, U.S. Patent No. 5,955,422, U.S. Patent No. 5,830,851, U.S. Patent No. 5,856,298, U.S. Patent No. 5,986,047, U.S. Patent No. 6,030,086, U.S. Patent No. 6,310,078, U.S. Patent No. 6,391,633, U.S. Patent No. 6,583,272, U.S. Patent No. 6,586,398, U.S. Patent No. 6,900,292,U.S. Patent No. 6,750,369, U.S. Patent No. 7,030,226, U.S. Patent No. 7,084,245, and U.S. Patent No. 7,217,689, U.S. Patent Application Publication No. 2002 / 0155998, U.S. Patent Application Publication No. 2003 / 0077753, U.S. Patent Application Publication No. 2003 / 0082749, U.S. Patent Application Publication No. 2003 / 0143202, U.S. Patent Application Publication No. 2004 / 0009902, U.S. Patent Application Publication No. 2004 / 0071694, U.S. Patent Application Publication No. 2004 / 0091961, U.S. Patent Application Publication No. 2004 / 0143857, U.S. Patent Application Publication No. 2004 / 0157293, U.S. Patent Application Publication No. 2004 / 0175379, U.S. Patent Application Publication No. 2004 / 0175824, U.S. Patent Application Publication No. 2004 / 0229318, U.S. Patent Application Publication No. 2004 / 0248815, U.S. Patent Application Publication No. 2004 / 0266690, U.S. Patent Application Publication No. 2005 / 0019914, U.S. Patent Application Publication No. 2005 / 0026834, US Patent Application Publication No. 2005 / 0096461, US Patent Application Publication No. 2005 / 0107297, US Patent Application Publication No. 2005 / 0107591, US Patent Application Publication No. 2005 / 0124045, US Patent Application Publication No. 2005 / 0124564, US Patent Application Publication No. 2005 / 0137329, US Patent Application Publication No. 2005 / 0142642, US Patent Application Publication No. 2005 / 0143292, US Patent Application Publication No. 2005 / 0153879, US Patent Application Publication No. 2005 / 0158822, U.S. Patent Application Publication No. 2005 / 0158832, U.S. Patent Application Publication No. 2005 / 0170457, U.S. Patent Application Publication No. 2005 / 0181359, U.S. Patent Application Publication No. 2005 / 0181482, U.S. Patent Application Publication No. 2005 / 0192211, U.S. Patent Application Publication No. 2005 / 0202538, U.S. Patent Application Publication No. 2005 / 0227289, U.S. Patent Application Publication No. 2005 / 0244409, U.S. Patent Application Publication No. 2006 / 0088906,and U.S. Patent Application Publication No. 2006 / 0111279, and PCT Publication Nos. WO 91 / 05867, WO 95 / 05465, WO 99 / 66054, WO 00 / 24893, WO 01 / 81405, WO 00 / 61637, WO 01 / 36489, WO 02 / 014356, WO 02 / 19963, WO 02 / 20034, WO 02 / 49673, WO 02 / 085940, WO 03 / 029291, WO 2003 / 055526, WO 2003 / 084477, WO 2003 / 094858, WO 2004 / 002417, WO 2004 / 002424, WO 2004 / 009627, WO 2004 / 024761, WO 2004 / 033 651, WO 2004 / 035603, WO 2004 / 043382, WO 2004 / 101600, WO 2004 / 101606, WO 2004 / 101611, WO 2004 / 106373, WO 2004 / 018667, WO 2005 / 001025, WO 2005 / 001136, WO 2005 / 021579 brochure, International Publication No. 2005 / 025606 pamphlet, International Publication No. 2005 / 032460 pamphlet, International Publication No. 2005 / 051327 pamphlet, International Publication No. 2005 / 063808 pamphlet, International Publication No. 2005 / 063809 pamphlet, International Publication No. 2005 / 070451 pamphlet, International Publication No. 2005 / 081687 pamphlet, International Publication No. 2005 / 084711 pamphlet, International Publication No. 2005 / 103076 pamphlet, International Publication No. 2005 / 100403 pamphlet,The erythropoietin molecules disclosed in WO 2005 / 092369, WO 2006 / 50959, WO 2006 / 02646, and WO 2006 / 29094, or variants or analogs thereof, are included.
[0077] Examples of other pharmaceuticals for use with the device may include, but are not limited to, antibodies such as Vectibix® (panitumumab), Xgeva™ (denosumab) and Prolia™ (denosumab); other biologics such as Enbrel® (etanercept, TNF receptor / Fc fusion protein, TNF blocker), Neulasta® (pegfilgrastim, PEGylated filgastrim, PEGylated G-CSF, PEGylated hu-Met-G-CSF), Neupogen® (filgrastim, G-CSF, hu-MetG-CSF), and Nplate® (romiplostim); small molecule drugs such as Sensipar® (cinacalcet). The device may also be used with therapeutic antibodies, polypeptides, proteins, or other chemicals such as iron, e.g., ferumoxytol, iron dextran, ferric gluconate, and ferric oxide. The pharmaceutical agent may be in liquid form or may be reconstituted from a lyophilized form.
[0078] Among certain exemplary proteins are the specific proteins described below, including fusions, fragments, analogs, variants, or derivatives thereof.
[0079] As disclosed in PCT Publication WO 03 / 002713, each of which is individually and specifically incorporated herein by reference in its entirety in its entirety, including OPGL-specific antibodies having either a light chain of SEQ ID NO:2 as set forth in Figure 2 of said publication and / or a heavy chain of SEQ ID NO:4 as set forth in Figure 4 of said publication, with regard to OPGL-specific antibodies and antibody-related proteins, in particular those having the sequences set forth in said publications, specifically but not limited to those set forth above (9H7, 18B2, 2D8, 2E11, 16E1, and 22B3), including but not limited to the antibodies described in said publications, which are incorporated herein in their entirety, OPGL-specific antibodies (also referred to as RANKL-specific antibodies, peptibodies, etc.), peptibodies, and related proteins, including fully humanized and human OPGL-specific antibodies, in particular fully humanized monoclonal antibodies;
[0080] TN8-19-1 through TN8-19-40, TN8-19 con1, and TN8-19 con2, each of which is individually and specifically incorporated herein by reference in its entirety as disclosed in U.S. Patent Application Publication No. 2004 / 0181033 and PCT Publication No. WO 2004 / 058988. myostatin binding proteins, peptibodies, and related proteins, including myostatin-specific peptibodies, which are described in the above publications, which are incorporated herein by reference in their entirety, in particular in part with respect to myostatin-specific peptibodies, including, but not limited to, the mTN8-19 family of peptibodies, including those of SEQ ID NOs: 305-351, including con2; the mL2 family of SEQ ID NOs: 357-383, the mL15 family of SEQ ID NOs: 384-409, the mL17 family of SEQ ID NOs: 410-438, the mL20 family of SEQ ID NOs: 439-446, the mL21 family of SEQ ID NOs: 447-452, the mL24 family of SEQ ID NOs: 453-454, and the peptibodies of SEQ ID NOs: 615-631;
[0081] L1H1, L1H2, L1H3, L1H4, L1H5, L1H6, L1H7, L1H8, L1H9, L1H10, L1H11, L2H1, L2H2, L2H3, L2H4, L2H5, L2H6, L2H7, L2H8, L2H9, L2H10, L2 ... , L2H11, L2H12, L2H13, L2H14, L3H1, L4H1, L5H1, L6H1, IL-4 receptor specific antibodies, particularly those antibodies as described in the above publications, including those particularly related in part to those set forth in the above publications, which are incorporated herein by reference in their entirety, and which inhibit activities mediated by IL-4 and / or IL-13 binding to the receptor, such as IL-4 receptor specific antibodies, peptibodies, and related proteins,
[0082] Interleukin 1-receptor 1 ("IL1-R1") specific antibodies, peptibodies, and related proteins, including, but not limited to, those set forth in U.S. Patent Application Publication No. 2004 / 097712, i.e., 15CA, 26F5, 27F2, 24E12, and 10H7, each of which is individually and specifically incorporated herein by reference in its entirety as disclosed in U.S. Patent Application Publication No. 2004 / 097712 ...
[0083] The sequences of the following publications, each of which is individually and specifically incorporated herein by reference in its entirety as disclosed in the following publications, in particular those sequences described in the following publications: L1(N), L1(N)WT, L1(N)1K WT, 2xL1(N), 2xL1(N)WT, Con4(N), Con4(N)1K WT, 2xCon4(N)1K, L1C, L1C 1K, 2xL1C, Con4C, Con4C 1K, 2xCon4C Ang2 specific antibodies and peptibodies, including, but not limited to, those described in PCT Publication No. WO 03 / 057134 and U.S. Patent Application Publication No. 2003 / 0229023, each of which is incorporated by reference in its entirety in part with particular reference to Ang2 specific antibodies and peptibodies, including, but not limited to, those described in the following publications ... Ang2 specific antibodies, peptibodies, and related proteins, including anti-Ang2 antibodies and formulations such as those described in PCT Publication WO 2003 / 030833, which is incorporated by reference in its entirety with respect to Ab533, Ab535, Ab536, Ab537, Ab540, Ab543, Ab544, Ab545, Ab546, A551, Ab553, Ab555, Ab558, Ab559, Ab565, AbF1AbFD, AbFE, AbFJ, AbFK, AbG1D4, AbGC1E8, AbH1C12, AblA1, AblF, AblK, AblP, and AblP;
[0084] NGF-specific antibodies, peptibodies, and related proteins, including, but not limited to, those described in U.S. Patent Application Publication No. 2005 / 0074821 and U.S. Patent No. 6,919,426, each of which is individually and specifically incorporated herein by reference in its entirety, specifically including, but not limited to, the NGF-specific antibodies 4D4, 4G6, 6H9, 7H2, 14D10, and 14D11 set forth in said publications, each of which is individually and specifically incorporated herein by reference in its entirety, and specifically including, but not limited to, those described in said publications, specifically including, but not limited to, the NGF-specific antibodies and related proteins set forth therein,
[0085] Humanized and fully human antibodies, including but not limited to, humanized and fully human monoclonal antibodies, including but not limited to, particularly human CD22 specific IgG antibodies, such as, for example, a dimer of human-mouse monoclonal hLL2 gamma chain disulfide linked to a human-mouse monoclonal hLL2 kappa chain, including, but not limited to, the human CD22 specific fully humanized antibody of epratuzumab (CAS Registry Number 501423-23-0), specifically human CD22 specific antibodies, CD22 specific antibodies, peptibodies, and related proteins, such as those described in U.S. Pat. No. 5,789,554, the entirety of which is incorporated herein by reference with respect to CD22 specific antibodies and related proteins;
[0086] The IGF-1 specific antibodies L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H28, L29H29, L30H30, L31H30, L32H30, L33H30, L34H30, L35H30, L36H30, L37H30, L38H30, L39 ... 31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51, L52H52, and IGF-1 R-binding fragments and derivatives thereof, including but not limited to those described in the above publications, which are incorporated by reference in their entireties herein with respect to IGF-1 receptor specific antibodies and related proteins;
[0087] Also among the non-limiting examples of anti-IGF-1R antibodies for use in the methods and compositions of the invention are each of those described below. (i) antibodies described in U.S. Patent Application Publication No. 2006 / 0040358 (published February 23, 2006), U.S. Patent Application Publication No. 2005 / 0008642 (published January 13, 2005), and U.S. Patent Application Publication No. 2004 / 0228859 (published November 18, 2004), including, but not limited to, antibody 1A (DSMZ Accession No. DSM ACC 2586), antibody 8 (DSMZ Accession No. DSM ACC 2589), antibody 23 (DSMZ Accession No. DSM ACC 2588), and antibody 18; (ii) antibodies, including but not limited to, 2F8, A12, and IMC-A12, described in PCT Publication No. WO 06 / 138729 (published December 28, 2006) and PCT Publication No. WO 05 / 016970 (published February 24, 2005), and Lu et al. (2004), J. Biol. Chem. 279:2856-2865; (iii) PCT Publication No. 07 / 012614 (published on February 1, 2007), PCT Publication No. 07 / 000328 (published on January 4, 2007), PCT Publication No. 06 / 013472 (published on February 9, 2006), PCT Publication No. 05 / 058967 (published on June 30, 2005), and PCT Publication No. 03 / 059951 (published on July 24, 2003); (iv) antibodies described in U.S. Patent Application Publication No. 2005 / 0084906 (published April 21, 2005), including, but not limited to, antibody 7C10, chimeric antibody C7C10, antibody h7C10, antibody 7H2M, chimeric antibody *7C10, antibody GM607, humanized antibody 7C10 version 1, humanized antibody 7C10 version 2, humanized antibody 7C10 version 3, and antibody 7H2HM; (v) antibodies including, but not limited to, EM164, resurfaced EM164, humanized EM164, huEM164 v1.0, huEM164 v1.1, huEM164 v1.2, and huEM164 v1.3, as described in U.S. Patent Application Publication No. 2005 / 0249728 (published November 10, 2005), U.S. Patent Application Publication No. 2005 / 0186203 (published August 25, 2005), U.S. Patent Application Publication No. 2004 / 0265307 (published December 30, 2004), and U.S. Patent Application Publication No. 2003 / 0235582 (published December 25, 2003), and Maloney et al. (2003) Cancer Res. 63:5073-5083; (vi) U.S. Pat. No. 7,037,498, issued May 2, 2006; U.S. Patent Application Publication No. 2005 / 0244408, published November 30, 2005; and U.S. Patent Application Publication No. 2004 / 0086503, published May 6, 2004; and Cohen, et al. (2005), Clinical Cancer Res. 11:2063-2073, including, but not limited to, each of the antibodies produced by hybridomas having ATCC Accession Nos. PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789, PTA-2793, and antibodies 2.12.1, 2.13.2, 2.14.3, 3.1.1, 4.9.2, and 4.17.3, e.g., antibody CP-751,871, (vii) including, but not limited to, antibody 19D12, as described in U.S. Patent Application Publication No. 2005 / 0136063, published June 23, 2005, and U.S. Patent Application Publication No. 2004 / 0018191, published January 29, 2004, and an antibody comprising a heavy chain encoded by the polynucleotide of plasmid 15H12 / 19D12 HCA(γ4), deposited with the ATCC under accession number PTA-5214, and a light chain encoded by the polynucleotide of plasmid 15H12 / 19D12 LCF(κ), deposited with the ATCC under accession number PTA-5220; (viii) including, but not limited to, the antibodies PINT-6A1, PINT-7A2, PINT-7A4, PINT-7A5, PINT-7A6, PINT-8A1, PINT-9A2, PINT-11A1, PINT-11A2, PINT-11A3, PINT-11A4, PINT-11A5, PINT-11A7, PINT-11A12, PINT-12A1, PINT-12A2, PINT-12A3, PINT-12A4, and PINT-12A5, which are described in U.S. Patent Application Publication No. 2004 / 0202655 (published October 14, 2004), each of which is incorporated herein by reference in its entirety with respect to the aforementioned antibodies, peptibodies, and related proteins that specifically target the IGF-1 receptor;
[0088] B-7 related protein 1 specific antibodies, peptibodies, related proteins and the like ("B7RP-1," also referred to in the literature as B7H2, ICOSL, B7h, and CD275), particularly B7RP specific fully human monoclonal IgG2 antibodies, particularly fully human IgG2 monoclonal antibodies that bind to an epitope in the first immunoglobulin-like domain of B7RP-1, particularly those that inhibit the interaction of B7RP-1 with ICOS, the natural receptor for B7RP-1, particularly on activated T cells, and ... as disclosed in the following publications, each of which is individually and specifically incorporated herein in its entirety by reference as disclosed in the following publications: 16H (within which the light and heavy chain variable region sequences have SEQ ID NOs: 1 and 7, respectively), 5D (within which the light and heavy chain variable region sequences have SEQ ID NOs: 1 and 7, respectively), and SEQ ID NOs: 2 and 3, respectively; and SEQ ID NO:9), 2H (having therein light chain variable region sequences and heavy chain variable region sequences, SEQ ID NO:3 and SEQ ID NO:10, respectively), 43H (having therein light chain variable region sequences and heavy chain variable region sequences, SEQ ID NO:6 and SEQ ID NO:14, respectively), 41H (having therein light chain variable region sequences and heavy chain variable region sequences, SEQ ID NO:5 and SEQ ID NO:13, respectively), and 15H (having therein light chain variable region sequences and heavy chain variable region sequences, SEQ ID NO:4 and SEQ ID NO:12, respectively) as disclosed in U.S. Patent Publication No. 2008 / 0166352 and PCT Publication No. WO 07 / 011941, which are incorporated by reference in their entireties with respect to such antibodies and related proteins, including, but not limited to, the antibodies set forth in the following publications:
[0089] IL-15 specific antibodies, peptibodies, and related proteins, particularly antibodies, particularly humanized monoclonal antibodies, such as those disclosed in U.S. Patent Application Publication Nos. 2003 / 0138421, 2003 / 023586, and 2004 / 0071702, and U.S. Patent Application Publication No. 7,153,507, each of which is incorporated herein by reference in its entirety for IL-15 specific antibodies and related proteins, including, inter alia, peptibodies, including, but not limited to, HuMax IL-15 antibody and related proteins, such as 146B7;
[0090] IFNγ-specific antibodies, peptibodies, and related proteins, and the like, particularly human IFNγ-specific antibodies, in particular fully human anti-IFNγ antibodies, such as, for example, IFNγ-specific antibodies, in particular, fully human anti-IFNγ antibodies, such as those described in U.S. Patent Application Publication No. 2005 / 0004353, which is incorporated herein by reference in its entirety for the antibodies designated 1118, 1118*, 1119, 1121, and 1121* in the following patent publications: The entire sequences of the heavy and light chains of each of these antibodies, and the sequences of their heavy and light chain variable regions and complementarity determining regions, are individually and specifically incorporated herein by reference in their entirety as disclosed in the aforementioned publications and in Thakur et al. (1999), Mol. Immunol. 36:1107-1115, respectively. In addition, the descriptions of the properties of these antibodies provided in the above publications are also incorporated herein by reference in their entirety. Specific antibodies include those having a heavy chain of SEQ ID NO:17 and a light chain of SEQ ID NO:18, those having a heavy chain variable region of SEQ ID NO:6 and a light chain variable region of SEQ ID NO:8, those having a heavy chain of SEQ ID NO:19 and a light chain of SEQ ID NO:20, those having a heavy chain variable region of SEQ ID NO:10 and a light chain variable region of SEQ ID NO:12, those having a heavy chain of SEQ ID NO:32 and a light chain of SEQ ID NO:20, those having a heavy chain variable region of SEQ ID NO:30 and a light chain variable region of SEQ ID NO:12, those having a heavy chain sequence of SEQ ID NO:21 and a light chain sequence of SEQ ID NO:22, those having a heavy chain variable region of SEQ ID NO:14 and a light chain variable region of SEQ ID NO:16, those having a heavy chain of SEQ ID NO:21 and a light chain of SEQ ID NO:33, and those having a heavy chain variable region of SEQ ID NO:14 and a light chain variable region of SEQ ID NO:31, as disclosed in the aforementioned publications. A specific antibody contemplated is antibody 1119, disclosed in the aforementioned U.S. Patent Application Publication, having the complete heavy chain of SEQ ID NO:17 disclosed in the aforementioned U.S. Patent Application Publication, and the complete light chain of SEQ ID NO:18 disclosed in the aforementioned U.S. Patent Application Publication;
[0091] TALL-1 specific antibodies, peptibodies, and related proteins, such as those described in the following publications, each of which is individually and specifically incorporated herein by reference in its entirety, as well as other TALL specific binding proteins, particularly those described in U.S. Patent Application Publication Nos. 2003 / 0195156 and 2006 / 0135431, each of which is incorporated herein by reference in its entirety with respect to the molecules in Tables 4 and 5B:
[0092] Parathyroid hormone ("PTH")-specific antibodies, peptibodies, and related proteins, such as those described in U.S. Pat. No. 6,756,480, which is incorporated by reference in its entirety, with particular reference in part to proteins that bind PTH;
[0093] Thrombopoietin receptor ("TPO-R")-specific antibodies, peptibodies, and related proteins, such as those described in U.S. Pat. No. 6,835,809, which is incorporated by reference in its entirety, with particular reference in part to proteins that bind TPO-R;
[0094] Hepatocyte growth factor ("HGF") specific antibodies, peptibodies, and related proteins, including those that target the HGF / SF:Met axis (HGF / SF:c-Met), such as fully human monoclonal antibodies that neutralize hepatocyte growth factor / scatter (HGF / SF), as described in U.S. Patent Application Publication No. 2005 / 0118643 and PCT Publication No. WO 2005 / 017107, huL2G7, as described in U.S. Patent No. 7,220,410, and OA-5d5, as described in U.S. Patent Nos. 5,686,292 and 6,468,529, and PCT Publication No. WO 96 / 38557, each of which is incorporated by reference in its entirety with particular reference in part to proteins that bind HGF;
[0095] TRAIL-R2 specific antibodies, peptibodies, related proteins, etc., such as those described in U.S. Pat. No. 7,521,048, which is incorporated by reference in its entirety, with particular reference in part to proteins that bind TRAIL-R2;
[0096] Activin A-specific antibodies, peptibodies, related proteins, etc., including, but not limited to, those described in U.S. Patent Application Publication No. 2009 / 0234106, which is incorporated by reference in its entirety, with particular reference in part to proteins that bind activin A;
[0097] TGF-β specific antibodies, peptibodies, related proteins, etc., including, but not limited to, those described in U.S. Pat. No. 6,803,453 and U.S. Patent Application Publication No. 2007 / 0110747, each of which is incorporated by reference in its entirety, with particular reference in part to proteins that bind TGF-β;
[0098] Amyloid β protein specific antibodies, peptibodies, related proteins, etc., including but not limited to those described in PCT Publication WO 2006 / 081171, which is hereby incorporated by reference in its entirety, particularly in relation to proteins that bind to amyloid β protein. One possible antibody is an antibody having a heavy chain variable region comprising SEQ ID NO:8 and a light chain variable region having SEQ ID NO:6, as disclosed in the above publication.
[0099] c-Kit specific antibodies, peptibodies, related proteins, etc., including, but not limited to, those described in U.S. Patent Application Publication No. 2007 / 0253951, which is incorporated by reference in its entirety, with particular reference in part to proteins that bind c-Kit and / or other stem cell factor receptors;
[0100] OX40L-specific antibodies, peptibodies, related proteins, and the like, including, but not limited to, those described in U.S. Patent Application Publication No. 2006 / 0002929, which is incorporated herein by reference in its entirety, with particular reference in part to proteins that bind OX40L and / or other ligands of the OX40 receptor;
[0101] Activase® (alteplase, tPA), Aranesp® (darbepoetin alfa), Epogen® (epoetin alfa, or erythropoietin), GLP-1, Avonex® (interferon beta-1a), Bexxar® (tositumomab, an anti-CD22 monoclonal antibody), Betaseron® (interferon-beta), Campath® (alemtuzumab, an anti-CD52 monoclonal antibody), Dynepo® (epoetin delta), Velcade® (bortezomib), MLN0002 (anti-alpha4beta7 mAb), MLN1202 (anti-CCR2 chemokine receptor mAb), Enbrel® (etanercept, TNF receptor / Fc fusion protein, TNF blocker), Eprex® (epoetin alfa), Erbitux® (cetuximab, anti-EGFR / HER1 / c-ErbB-1), Genotropin® (somatropin, human growth hormone), Herceptin® (trastuzumab, anti-HER2 / neu(erbB2) receptor mAb), Huma trope® (somatropin, human growth hormone), Humira® (adalimumab), insulin in solution, Infergen® (interferon alfacon-1), Natrecor® (nesiritide, recombinant human B-type natriuretic peptide (hBNP), Kineret® (anakinra), Leukine® (sargamostim, rhuGM-CSF), LymphoCide® (epratuzumab, anti-CD22 mAb), Benlysta™ (lymphostat B, belimumab, anti-BlySmAb), Metalyse® (tenecteplase, t-PA analog), Mircera® (methoxypolyethylene glycol-epoetin beta), Mylotarg® (gemtuzumab ozogamicin), Raptiva® (efalizumab), Cimzia® (certolizumab pegol, CDP870), Soliris™ (eculizumab), pexelizumab (anti-complement C5), Numax® (MEDI-524), Lucentis® (ranibizumab), Panorex® (17-1A, edrecolomab), Trabio® (lerdelimumab), TheraCim hR3 (nimotuzumab), Omnitarg (pertuzumab, 2C4), Osidem® (IDM-1), OvaRex® (B43.13), Nuvion® (vigilizumab), cantuzumab mertansine (huC242-DM1), NeoRecormon® (epoetin beta), Neumega® (oprelvekin, human interleukin-11), Neulasta® (PEGylated filgastrim, PEGylated G-CSF, PEGylated hu-Met-G-CSF), Neupogen® (filgrastim, G-CSF, hu-MetG-CSF), Orthoclone OKT3® (muromonab-CD3, anti-CD3 monoclonal antibody), Procrit® (epoetin alfa), Remicade® (infliximab, anti-TNFα monoclonal antibody), Reopro® (abciximab, anti-GP lIb / Ilia receptor monoclonal antibody), Actemra® (anti-IL6 receptor mAb), Avastin® (bevacizumab), HuMax-CD4 (zanolimumab), Rituxan® (rituximab, anti-CD20mAb), Tarceva® (erlotinib), Roferon-A® (interferon alfa-2a), Simulect® (basiliximab), Prexige® (lumiracoxib), Synagis® (palivizumab), 146B7-CHO (anti-IL15 antibody, see U.S. Pat. No. 7,153,507), Tysabri® (natalizumab, anti-α4 integrin mAb), Valortim® (MDX-1303, anti-anthrax protective antigen mAb), ABthrax™, Vectibix® (panitumumab), Xolair® (omalizumab), ETI211 (anti-MRSA mAb), IL-1 trap (the Fc portion of human IgG1 and the extracellular domains of both IL-1 receptor components (type I receptor and receptor accessory protein)), VEGF trap (the Ig domain of VEGFR1 fused to IgG1 Fc), Zenapax® (daclizumab), Zenapax® (daclizumab, anti-IL-2Rα mAb), Zevalin® (ibritumomab tiuxetan), Zetia® (ezetimibe), Orencia® (atacicept, TACI-Ig), anti-CD80 monoclonal antibody (galiximab), anti-CD23 mAb (lumiliximab), BR2-Fc (huBR3 / huFc fusion protein, soluble BAFF antagonist), CNTO148 (golimumab, anti-TNFα mAb), HGS-ETR1 (mapatuzumab, human anti-TRAIL receptor-1 mAb), HuMax-CD20 (ocrelizumab, anti-CD20 human mAb), HuMax-EGFR (zalutumumab), M200 (volociximab, anti-α5β1 integrin mAb), MDX-010 (ipilimumab, anti-CTLA-4 mAb, and VEGFR-1 (IMC-18F1), anti-BR3 mAb, anti-C. difficile toxin A and toxin BC mAbs MDX-066 (CDA-1) and MDX-1388), anti-CD22 dsFv-PE38 conjugate (CAT-3888 and CAT-8015), anti-CD25 mAb (HuMax-TAC), anti-CD3 mAb (NI-0401), adecatumumab, anti-CD30mAb (MDX-060), MDX-1333 (anti-IFNAR), anti-CD38 mAb (HuMax CD38), anti-CD40L mAb, anti-Cripto mAb, anti-CTGF Idiopathic Pulmonary Fibrosis Phase 1 Fibrinogen (FG-3019), anti-CTLA4 mAb, anti-Eotaxin 1 mAb (CAT-213), anti-FGF8 mAb, anti-Ganglioside GD2 mAb, anti-Ganglioside GM2 mAb, anti-GDF-8 Human mAb (MYO-029), anti-GM-CSF Receptor mAb (CAM-3001), anti-HepC mAb (HuMax HepC), anti-IFNα mAb (MEDI-545, MDX-1103), anti-IGF1R mAb, anti-IGF-1R mAb (HuMax-Inflam), anti-IL12 mAb (ABT-874), anti-IL12 / IL23 mAb (CNTO1275), anti-IL13 mAb (CAT-354), anti-IL2Ra mAb (HuMax-TAC), anti-IL5 Receptor mAb, anti-Integrin Receptor mAb (MDX-018, CNTO95), anti-IP10 Ulcerative Colitis mAb (MDX-1100), anti-LLY Antibody, BMS-66513, anti-Mannose Receptor / hCGβ mAb (MDX-1307), anti-Mesothelin dsFv-PE38 Conjugate (CAT-5001), anti-PD1 mAb (MDX-1106 (ONO-4538)), anti-PDGFRα Antibody (IMC-3G3), anti-TGFβ mAb (GC-1008), anti-TRAIL Receptor-2 Human mAb (HGS-ETR2), anti-TWEAK mAb, anti-VEGFR / Flt-1 mAb, anti-ZP3 mAb (HuMax-ZP3), NVS Antibody No. 1, and NVS Antibody No. 2, and other exemplary proteins.
[0102] Sclerostin antibodies, such as, but not limited to, romosozumab, brosozumab, or BPS804 (Novartis), may also be included. Further therapeutic agents may be included, such as rilotumumab, bixalomer, trebananib, ganitumab, conatumumab, motesanib diphosphate, brodalumab, vidupiprant, panitumumab, denosumab, NPLATE, PROLIA, VECTIBIX, or XGEVA. Additionally, monoclonal antibodies (IgG) that bind to human proprotein convertase subtilisin / kexin type 9 (PCSK9) may be included in the device.Such PCSK9-specific antibodies include those described in the following patents or patent applications, each of which is incorporated herein by reference in its entirety for all purposes: U.S. Pat. No. 8,030,547, U.S. Patent Application Publication No. 2013 / 0064825, WO 2008 / 057457, WO 2008 / 057458, WO 2008 / 057459, WO 2008 International Publication No. 2008 / 133647, International Publication No. 2009 / 100297, International Publication No. 2009 / 100318, International Publication No. 2011 / 037791, International Publication No. 2011 / 053759, International Publication No. 2011 / 053783, International Publication No. 2008 / 125623, International Publication No. 2 International Publication No. 011 / 072263, International Publication No. 2009 / 055783, International Publication No. 2012 / 0544438, International Publication No. 2010 / 029513, International Publication No. 2011 / 111007, International Publication No. 2010 / 077854, International Publication No. 2012 / 088313, International Publication No. 2012 / 101251, International These include, but are not limited to, Repatha® (evolocumab) and Praluent® (alirocumab) and molecules, variants, analogs, or derivatives thereof as disclosed in Publication No. WO 2012 / 101252, WO 2012 / 101253, WO 2012 / 109530, and WO 2001 / 031007.
[0103] Also included may be talimogene laherparepvec or another oncolytic HSV for the treatment of melanoma or other cancers. Examples of oncolytic HSV include, but are not limited to, talimogene laherparepvec (U.S. Pat. Nos. 7,223,593 and 7,537,924), OncoVEXGALV / CD (U.S. Pat. No. 7,981,669), OrienX010 (Lei et al. (2013), World J. Gastroenterol., 19:5138-5143), G207, 1716, NV1020, NV12023, NV1034, and NV1042 (Vargehes et al. 2002), Cancer Gene Ther., 9(12):967-978).
[0104] Also included are TIMPs. TIMPs are endogenous tissue inhibitors of metalloproteinases (TIMPs) and are important in many natural processes. TIMP-3 is expressed by various cells and / or present in the extracellular matrix, inhibits all major cartilage-degrading metalloproteases, and may play a role in many degradative diseases of connective tissue, including rheumatoid arthritis and osteoarthritis, as well as in cancer and cardiovascular conditions. The amino acid sequence of TIMP-3 and the nucleic acid sequence of DNA encoding TIMP-3 are disclosed in U.S. Patent No. 6,562,596, issued May 13, 2003, the disclosure of which is incorporated herein by reference. Descriptions of TIMP mutations can be found in U.S. Patent Application Publication No. 2014 / 0274874 and PCT Application Publication No. WO 2014 / 152012.
[0105] Also included are antagonistic antibodies of the human calcitonin gene-related peptide (CGRP) receptor and bispecific antibody molecules targeting the CGRP receptor and other headache targets. More information regarding these molecules can be found in PCT Application No. WO 2010 / 075238.
[0106] Additionally, bispecific T cell engaging (BiTe®) antibody constructs, such as BLINCYTO® (blinatumomab), can be used in the device. Alternatively, an APJ macromolecule agonist, such as apelin or an analog thereof, can be included in the device. Information regarding such molecules can be found in WO 2014 / 099984.
[0107] As used herein, the term "bispecific" refers to an antibody construct comprising at least a first binding domain and a second binding domain, where the first binding domain binds to one antigen or target and the second binding domain binds to another antigen or target on a T cell. A preferred bispecific antibody construct according to the present invention may also be defined as an antibody construct comprising a first binding domain that binds to a human antigen on the surface of a target cell and a second binding domain that binds to human CD3 on the surface of a T cell. Methods for preparing fused and operably linked bispecific antigen constructs and expressing them in mammalian cells or bacteria are well known in the art (e.g., WO 99 / 54440).
[0108] The present invention provides preferred embodiments, in which the bispecific antibody construct is in a format selected from the group consisting of (scFv)2, scFv-single domain mAb, diabodies and oligomers of any of these formats. According to a particularly preferred embodiment, the antibody construct of the present invention is a bispecific single chain antibody construct, more preferably a bispecific single chain Fv (scFv).
[0109] In some embodiments, the medicament comprises a therapeutically effective amount of anti-thymic stromal lymphopoietin (TSLP) or a TSLP receptor antibody. Examples of anti-TSLP antibodies that may be used in such embodiments include, but are not limited to, those described in U.S. Patent Nos. 7,982,016 and 8,232,372, and U.S. Patent Publication No. 2009 / 0186022. Examples of anti-TSLP receptor antibodies include, but are not limited to, those described in U.S. Patent No. 8,101,182. In a particularly preferred embodiment, the medicament comprises a therapeutically effective amount of the anti-TSLP antibody designated A5 in U.S. Patent No. 7,982,016.
[0110] Although the drug delivery device, method, and components thereof have been described in terms of exemplary embodiments, the drug delivery device, method, and components thereof are not limited thereto. The detailed description is to be construed as an example only and does not describe all possible embodiments of the invention, since describing every single one of the possible embodiments would be impractical, if not impossible. Many alternative embodiments can be implemented using either current technology or technology developed after the filing date of this patent, and such embodiments still fall within the scope of the claims that define the invention. For example, components described herein with reference to a particular type of drug delivery device, such as an on-body injector drug delivery device, or other types of drug delivery devices, can also be utilized in other types of drug delivery devices, such as an autoinjector drug delivery device.
[0111] Those skilled in the art will understand that numerous modifications, alterations, and combinations can be made to the above-described embodiments without departing from the scope of the present invention, and such modifications, alterations, and combinations are to be construed as falling within the scope of the inventive concept.
Claims
1. a reservoir filled or fillable with a first drug product; a dispensing member insertable into a patient and connected or connectable in fluid communication with said reservoir; a fluid delivery system operable to deliver the first drug product from the reservoir to the patient via the dispensing member; a sensor operable to sense a biological condition of the patient; Including, the system.
2. The system of claim 1 , comprising a controller configured to control operation of the fluid delivery system based on the sensed biological condition.
3. 3. The system of claim 2, wherein the controller is configured to operate the fluid delivery system to interrupt, terminate, or inhibit delivery of the first drug product to the patient based on the sensed biological condition.
4. The system of claim 2 or 3, wherein the controller is configured to operate an output unit to notify the patient and / or a healthcare provider based on the sensed biological condition.
5. A system according to any one of claims 1 to 4, comprising a second reservoir filled or fillable with a second drug product.
6. 6. The system of claim 5, wherein the controller is configured to operate the fluid delivery system to initiate delivery of the second drug product to the patient based on the sensed biological condition.
7. 7. The system of claim 5 or 6, wherein the second drug product comprises an agent for treating or managing a condition or syndrome induced by administration of the first drug product.
8. The system of any one of claims 5 to 7, wherein the first drug product comprises an immunotherapeutic agent and the second drug product comprises an anti-cytokine agent.
9. a second sensor operable to sense a second biological condition of the patient; the controller is configured to operate the fluid delivery system to interrupt, terminate or inhibit delivery of the first drug product to the patient in response to a determination that (i) the sensed biological condition is within or outside a predetermined range of values or is above or below a predetermined value, and / or (ii) the sensed second biological condition is within or outside a second predetermined range of values or is above or below a second predetermined value. The system of claim 2.
10. a second reservoir filled or fillable with a second drug product; The controller is configured to operate the fluid delivery system to initiate delivery of the second drug product to the patient in response to a determination that (i) the sensed biological condition is within or outside a predetermined range of values or is above or below a predetermined value, and / or (ii) the second sensed biological condition is within or outside a second predetermined range of values or is above or below a second predetermined value.
10. The system according to claim 2 or 9.
11. 11. The system of claim 10, wherein the second drug product comprises an agent for treating or managing a condition or syndrome induced by administration of the first drug product.
12. The system of any one of claims 9 to 11, wherein the second sensor is operable to sense a body temperature of the patient.
13. 3. The system of claim 2, wherein the controller is configured to operate the fluid delivery system to initiate delivery of the first drug product to the patient in response to a determination that the sensed biological condition is within or outside a predetermined value range, or above or below a predetermined value.
14. a second sensor operable to sense a second biological condition of the patient; The controller is configured to operate the fluid delivery system to initiate delivery of the first drug product to the patient in response to a determination that (i) the sensed biological condition is within or outside a predetermined range of values or is above or below a predetermined value, and / or (ii) the second sensed biological condition is within or outside a second predetermined range of values or is above or below a second predetermined value. The system of claim 2.
15. The system of claim 14 , wherein the second sensor is operable to sense a temperature of the patient.
16. The system of any one of claims 13 to 15, wherein the first drug product comprises an anti-cytokine agent.
17. The system of any one of claims 1 to 16, wherein the sensed biological condition comprises a biochemical level or a change in a biochemical level.
18. The system of claim 17 , wherein the biochemical substances include cytokines and / or biomarkers indicative of cytokine release syndrome.
19. The system of any one of claims 1 to 18, wherein the sensor is operable to sense the biological condition of the patient by analysing sweat produced by the patient.
20. 20. The system of any one of claims 1 to 19, wherein the first drug product comprises a bispecific T cell engaging antibody construct and / or a chimeric antigen receptor (CAR) T cell receptor.
21. the first drug product comprises a bispecific T cell engaging antibody construct and / or a chimeric antigen receptor (CAR) T cell receptor; the second product comprises a corticosteroid and / or an anti-interleukin-6 (IL-6) receptor antibody; 11. The system of claim 5, 6 or 10.
22. A system according to any one of claims 1 to 21, wherein the fluid delivery system comprises a pump connected or connectable in fluid communication with the dosing member and / or the reservoir.
23. 23. The system of any one of claims 1 to 22, comprising a housing including an interior space and configured to be worn by the patient, the reservoir being disposed or configured to be disposed within the interior space of the housing.
24. 24. The system of claim 23, including an adhesive layer attached to an exterior surface of the housing for attaching the housing to the patient's skin.
25. 25. The system of claim 24, wherein the dispensing member has a retracted state in which the dispensing member is retracted within the interior space of the housing and a deployed state in which an end of the dispensing member protrudes beyond the exterior surface of the housing.
26. 26. The system of claim 25, comprising an introducer member that extends from the end of the administration member during deployment of the administration member and then retracts toward the housing prior to drug delivery.
27. 27. The system of any one of claims 23 to 26, wherein the reservoir includes a plunger movable within a bore to expel the first drug product from the reservoir.
28. 28. The system of claim 27, wherein the fluid delivery system includes a motor, a spring, osmosis, and / or a source of pressurized gas or fluid operable upon actuation to drive the plunger within the bore.
29. The system of any one of claims 23 to 28, wherein the controller is disposed within the interior space of the housing.
30. A system according to any one of claims 2 to 29, wherein the controller comprises a microprocessor.
31. A system according to any one of claims 23 to 30, comprising a second reservoir filled or fillable with a second drug product, the second reservoir being located or positionable within the interior space of the housing.
32. 32. The system of claim 31, wherein the controller is configured to operate the fluid delivery system to initiate delivery of the second drug product to the patient in response to a determination that the sensed biological condition is within or outside a predetermined value range, or above or below a predetermined value.
33. 33. The system of claim 31 or 32, wherein the second drug product comprises an agent for treating or managing a condition or syndrome induced by administration of the first drug product.
34. The system of any one of claims 31 to 33, wherein the first drug product comprises an immunotherapeutic agent and the second drug product comprises an anti-cytokine agent.
35. The system of any one of claims 1 to 34, wherein the administration member is insertable into a patient's vein for intravenous drug delivery.
36. The system of any one of claims 1 to 34, wherein the administration member is insertable into subcutaneous tissue of a patient for subcutaneous drug delivery.
37. 37. The system of any one of claims 1 to 36, wherein the fluid delivery system includes a reconstitution subsystem, the first drug product includes a lyophilized drug, and the reconstitution subsystem is configured to reconstitute the lyophilized drug prior to delivery to the patient via the administration member.
38. 38. The system of claim 37, comprising a third reservoir filled or fillable with a diluent for reconstituting the lyophilized drug.
39. operating the fluid delivery system to deliver a first drug product from the reservoir to the patient via the dosing member; sensing a biological state of the patient during, before, and / or after delivery of the first drug product with a sensor; A method comprising:
40. 40. The method of claim 39, comprising operating the fluid delivery system to interrupt, terminate, or inhibit delivery of the first drug product to the patient based on the sensed biological condition.
41. 40. The method of claim 39, comprising automatically operating the fluid delivery system by a controller to interrupt, terminate, or inhibit delivery of the first drug product to the patient based on the detected biological condition.
42. 42. The method of any one of claims 39 to 41, comprising operating the fluid delivery system to initiate delivery of a second drug product from a second reservoir to the patient based on the sensed biological condition.
43. 42. The method of any one of claims 39-41, comprising automatically operating the fluid delivery system by the controller to initiate delivery of a second drug product from a second reservoir to the patient based on the sensed biological condition.
44. 44. The method of claim 42 or 43, wherein the second drug product comprises an agent for treating or managing a condition or syndrome induced by administration of the first drug product.
45. 45. The method of any one of claims 42-44, wherein the first drug product comprises an immunotherapeutic agent and the second drug product comprises an anti-cytokine agent.
46. sensing a second biological condition of the patient with a second sensor; automatically or manually operating the fluid delivery system by the controller to interrupt, terminate or inhibit delivery of the first drug product to the patient when (i) the sensed biological condition is within or outside a predetermined range of values or above or below a predetermined value, and / or (ii) the sensed second biological condition is within or outside a second predetermined range of values or above or below a second predetermined value; The method according to any one of claims 39 to 45, comprising:
47. 47. The method of claim 46, comprising automatically or manually operating the fluid delivery system by the controller to initiate delivery of a second drug product from a second reservoir to the patient when (i) the detected biological condition is within or outside the predetermined value range or is above or below the predetermined value, and / or (ii) the second detected biological condition is within or outside the second predetermined value range or is above or below the second predetermined value.
48. 48. The method of claim 47, wherein the second drug product comprises an agent for treating or managing a condition or syndrome induced by administration of the first drug product.
49. A method according to any one of claims 46 to 48, wherein the second sensor is operable to sense a body temperature of the patient.
50. sensing a second biological condition of the patient with a second sensor; automatically or manually operating the fluid delivery system by the controller to initiate delivery of the first drug product to the patient when (i) the sensed biological condition is within or outside of the predetermined range of values or above or below the predetermined value, and / or (ii) the sensed second biological condition is within or outside a second predetermined range of values or above or below a second predetermined value; The method according to any one of claims 39 to 41, comprising:
51. 51. The method of claim 50, wherein the second sensor is operable to sense a body temperature of the patient.
52. 52. The method of any one of claims 39 to 51, comprising automatically operating an output unit by the controller to notify the patient and / or a healthcare provider that the sensed biological condition is within or outside of the predetermined value range, or above or below the predetermined value.
53. 53. The method of any one of claims 39 to 52, wherein the sensed biological condition comprises a biochemical level or a change in a biochemical level.
54. 54. The method of claim 53, wherein the biochemicals include cytokines and / or biomarkers indicative of cytokine release syndrome.
55. A method according to any one of claims 39 to 54, wherein the sensor is operable to sense the biological condition of the patient by analysing sweat produced by the patient.
56. 55. The method of any one of claims 37 to 52 to 54, wherein the first drug product comprises a bispecific T cell engaging antibody construct and / or a chimeric antigen receptor (CAR) T cell receptor.
57. the first drug product comprises a bispecific T cell engaging antibody construct and / or a chimeric antigen receptor (CAR) T cell receptor; the second drug product comprises a corticosteroid and / or an anti-interleukin-6 (IL-6) receptor antibody; 50. The method according to any one of claims 42 to 45 or 47 to 49.
58. 58. The method of any one of claims 39 to 57, comprising adhering a housing to the patient's skin, the housing defining an interior space in which the reservoir is disposed.
59. 59. The method of claim 58, further comprising automatically or manually operating the fluid delivery system by the controller to initiate delivery of a second drug product to the patient from a second reservoir, the second reservoir being disposed within the interior space of the housing, when the detected biological condition is within or outside the predetermined value range, or above or below the predetermined value.
60. 60. The method of claim 59, wherein the second drug product comprises an agent for treating or managing a condition or syndrome induced by administration of the first drug product.
61. 61. The method of claim 59 or 60, wherein the first pharmaceutical product comprises an immunotherapeutic agent and the second pharmaceutical product comprises an anti-cytokine agent.
62. 62. The method of any one of claims 39 to 61, wherein operating the fluid delivery system to deliver the first drug product from the reservoir to the patient via the dosing member comprises delivering the first drug product intravenously.
63. 62. The method of any one of claims 39 to 61, wherein operating the fluid delivery system to deliver the first drug product from the reservoir to the patient via the dosing member comprises delivering the first drug product to a subcutaneous tissue of the patient.
64. 62. The method of any one of claims 42-45, 47-49, 56, or 59-61, wherein operating the fluid delivery system to deliver the first drug product from the reservoir to the patient via the dosing member comprises delivering the first drug product intravenously or to a subcutaneous tissue of the patient, and operating the fluid delivery system to deliver the second drug product from the reservoir to the patient comprises delivering the second drug product intravenously or to a subcutaneous tissue of the patient.
65. 65. A method according to any one of claims 39 to 64, comprising taking a blood sample from the patient by drawing blood up along the axis of a drug delivery needle.
